methadone has been researched along with naltrexone in 438 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 90 (20.55) | 18.7374 |
| 1990's | 46 (10.50) | 18.2507 |
| 2000's | 83 (18.95) | 29.6817 |
| 2010's | 122 (27.85) | 24.3611 |
| 2020's | 97 (22.15) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Geller, I; Hartmann, RJ | 1 |
| Ladewig, D | 1 |
| Resnick, RB; Volavka, J | 1 |
| Grabowski, J; Jordan-Hayes, J; O'Brien, CP; Ternes, JW; Wellerstein, H | 1 |
| Chipkin, RE; Rosecrans, JA | 1 |
| Ling, W | 2 |
| Rawson, RA; Resnick, RB; Washton, AM | 1 |
| Altman, JL; Meyer, RE; Mirin, SM | 1 |
| Terenius, L | 1 |
| Wikler, A | 2 |
| Greenstein, R; O'Brien, CP; Woody, GE | 1 |
| Kestenbaum, RS; Resnick, RB; Thomas, MA; Washton, AM | 1 |
| Hui, FW; Krikun, E; Smith, AA | 1 |
| Johnson, JH; Maughan, GT; Rosecrans, JA | 1 |
| Blakis, M; Haas, N; Holmes, E; Ling, W; Litaker, M | 1 |
| Keegan, J; Lavenduski, C; Schooff, K | 1 |
| Cooperstein, J; Harris, M; Hough, G; Kauders, F; Resnick, R; Thomas, M | 1 |
| Inturrisi, CE | 1 |
| Brocco, MJ; Killam, KF; Robinson, CA | 1 |
| Kestenbaum, RS; Poole, D; Resnick, RB; Washton, A | 1 |
| Hollister, LE; Kasper, P; Schwin, RL | 1 |
| Swanson, DA | 1 |
| Blaiklock, RG; Hirsh, EM; Hui, FW; Krikun, E; Smith, AA | 1 |
| Gray, AP; Guardina, WJ | 2 |
| McNamee, HB; Meyer, RE; Mirin, SM | 1 |
| Amico, L; Landsberg, R; Plumb, M; Taintor, Z; Wicks, N | 1 |
| Chen, RC; Ho, AK | 1 |
| Goldstein, A | 2 |
| Greenstein, RA; Mintz, J; O'Brien, CP; Woody, GE | 1 |
| Kauders, F; Schecter, A | 1 |
| Craft, RM; Dykstra, LA | 1 |
| Maneckjee, R; Minna, JD | 1 |
| Billings, B; Candido, J; Duttaroy, A; Inturrisi, CE; Lutfy, K; Sierra, V; Yoburn, BC | 1 |
| Kleber, HD; Kosten, TR; Morgan, C | 3 |
| Bilsky, EJ; Delong, CL; Montegut, MJ; Reid, LD | 1 |
| Goldberg, SR; Grayson, NA; Jaffe, JH; Johnson, RE; Katz, JL; Rice, KC; Witkin, JM | 1 |
| Lenz, K; Loimer, N; Presslich, O; Schmid, R | 2 |
| Caballero, L; Iruela, LM; Oliveros, SC | 1 |
| Ling, W; Wesson, DR | 1 |
| LoPresti, D; Porreca, F; Ward, SJ | 1 |
| Dykstra, LA | 1 |
| Adams, JU; Holtzman, SG; Paronis, CA | 1 |
| Fraser, AD | 1 |
| Charney, DS; Kleber, HD; Kosten, TR; Krystal, JH; Morgan, CH; Price, LH | 1 |
| Bronson, ME; Sparber, SB | 1 |
| Woody, G | 1 |
| Schuster, CR; Snyder, M | 1 |
| Fram, DH; Holden, R; Marmo, J | 1 |
| Eriksson, I; McLellan, AT; Nyberg, F; O'Brien, CP; Terenius, LY | 1 |
| Di Chiara, G; Imperato, A | 1 |
| Carino, MA; Horita, A; Yamawaki, S | 1 |
| Peachey, JE | 1 |
| Harty, GJ; Onofrio, BM; Yaksh, TL | 1 |
| Adams, M; Cushman, P; Dewey, W; Morris, D | 1 |
| Kleber, HD | 2 |
| Hynes, MD; Leander, JD; Reel, JK; Zimmerman, DM | 1 |
| Gossop, M | 1 |
| McLellan, AT; Nyberg, F; O'Brien, CP; Terenius, LY | 1 |
| Brahen, LS; Capone, DM; Capone, TJ | 1 |
| Williams, A | 1 |
| Agren, H | 1 |
| Kleber, HD; Kosten, TR; Rounsaville, BJ | 1 |
| Charney, DS; Heninger, GR; Kleber, HD | 1 |
| Grey, C; Osborn, E; Reznikoff, M | 2 |
| Mello, NK; Mendelson, JH | 1 |
| Moerschbaecher, JM; Thompson, DM; Winsauer, PJ | 1 |
| Rawson, RA; Resnick, RB; Tennant, FS; Washton, AM | 2 |
| Extein, I; Gold, MS; Kleber, HD; Pottash, AL | 2 |
| Resnick, RB; Washton, AM | 4 |
| Cerdeño Impuesto, V | 1 |
| Clemens, JA; Shaar, CJ | 1 |
| Schecter, A | 1 |
| Extein, I; Gold, MS; Kleber, HD; Martin, D; Pottash, AC | 1 |
| Frantz, AG; Kreek, MJ; Ragavan, VV; Wardlaw, SL | 1 |
| Frenk, H; Mayer, DJ; Miller, J; Watkins, LR | 1 |
| Goldstein, A; Inturrisi, CE; Judson, BA | 1 |
| Childress, AR; Ehrman, RN; McLellan, AT; O'Brien, CP; Ternes, J | 1 |
| Dackis, CA; Gold, MS | 1 |
| Bigelow, GE; Sherman, MF; Singleton, EG | 1 |
| Kleber, HD; Kosten, TR | 1 |
| Charney, DS; Galloway, MP; Heninger, GR; Kleber, HD; Murberg, M; Redmond, DE; Roth, RH | 1 |
| Greenstein, RA; Resnick, E; Resnick, RB | 1 |
| Lynch, MR; Porter, JH; Rosecrans, JA | 1 |
| Domino, EF; Ruffing, DM | 1 |
| Krivoy, W; McLellan, AT; O'Brien, CP; Terenius, L; Wahlström, A | 1 |
| Crits-Christoph, K; Kleber, H; Rounsaville, BJ; Weissman, MM; Wilber, C | 1 |
| Braverman, P; Charney, DS; Heninger, GR; Kleber, HD; Murburg, M; Redmond, DE; Riordan, CE; Sternberg, DE | 1 |
| Kirlangitis, J; Langley, AE; Lehman, TM; Zeid, R | 1 |
| Johnson, JH; Rosecrans, JA | 1 |
| Murphy, MR | 1 |
| Jasinski, DR | 1 |
| Kuehnle, JC; Mello, NK; Mendelson, JH; Sellers, MS | 1 |
| Wodak, A | 1 |
| Miguel, N; Patricio, LD | 1 |
| Cavigliano, P; Fossati, G; Frigo, G; Lecchini, S; Mazzone, A; Mazzucchelli, I; Notario, A; Pasotti, D; Ricevuti, G | 1 |
| Chang, KJ; Dykstra, LA; McNutt, R; Schoenbaum, GM; Yarbrough, J | 1 |
| KOSTEN, TR | 1 |
| Cutler, R; Fishbain, DA; Rosomoff, HL | 1 |
| Gold, MS | 1 |
| Chami, TN; Cheskin, LJ; Jaffe, JH; Johnson, RE | 1 |
| Greenwood, J; Seivewright, NA | 1 |
| Rounsaville, BJ | 1 |
| Hajak, G; Poser, W; Rodenbeck, A; Rüther, E; Staedt, J; Stoppe, G; Wassmuth, F | 1 |
| Simon, DL | 1 |
| Ehrenreich, H; Poser, W | 1 |
| Blansfield, HN | 1 |
| Brandt, MR; Cabansag, SR; France, CP | 1 |
| Fawcett, JP; Morgan, NC; Woods, DJ | 1 |
| Gutiérrez Mora, E; Lozano Polo, JL; Martínez Pérez, V; Santamaría Gutiérrez, J; Vada Sánchez, J; Vallejo Correas, JA | 1 |
| Barr, GA; Hamowy, AS; Hutchings, DE; Liu, PY; Wang, S; Zmitrovich, A | 1 |
| Cheung, P; Li, JG; Liu-Chen, LY; Raffa, RB; Tzeng, TB | 1 |
| Bargagli, AM; D'Ippoliti, D; Davoli, M; Pasqualini, F; Perucci, CA | 1 |
| Bertschy, G; Cucchia, AT; Ferrero, F; Monnat, M; Spagnoli, J | 1 |
| Morgan, D; Picker, MJ | 1 |
| Hall, W; Mattick, RP; Ward, J | 1 |
| Hirtl, C; Pfab, R; Zilker, T | 1 |
| Simpson, S | 1 |
| Hall, WD; Wodak, A | 1 |
| Bammer, G; Bell, JR; Masterman, SC; Mattick, RP; Morris, A; Young, MR | 1 |
| Barelli, A; De Giacomo, M; Gaspari, R; Mannelli, P; Stefanelli, A | 1 |
| Foss, FJ; Moss, J; O'Connor, M; Osinski, J; Roizen, FM; Yuan, SC | 1 |
| De Giacomo, M; De Risio, S; Janiri, L; Mannelli, P; Pozzi, G | 1 |
| Foss, JF; Karrison, T; Moss, J; O'Connor, M; Osinski, J; Roizen, MF; Yuan, CS | 1 |
| Sutherland, J; Walker, EA; Young, AM; Zhang, L | 1 |
| Hensel, M; Kox, WJ | 1 |
| Bocchi, C; Delsignore, R; Fontanesi, B; Gerra, G; Rustichelli, P; Timpano, M; Zaimovic, A; Zambelli, U | 1 |
| Conte, G; De Risio, S; Pozzi, G | 1 |
| Fiellin, DA; O'Connor, PG | 1 |
| Bearn, J; Buntwal, N; Gossop, M; Strang, J | 1 |
| Scholz, M | 1 |
| Farrell, M; Keaney, F | 1 |
| Cañadas, F; Rice, KC; Riley, AL; Stevenson, GW; Zhang, X | 1 |
| Foss, JF; Yuan, CS | 1 |
| Borg, L; Carson, RE; Eckelman, WC; Herscovitch, P; Ho, A; Kling, MA; Kreek, MJ; Matochik, JA; Rice, KC; Schluger, J; Zametkin, A | 1 |
| Bisaga, A; Popik, P; Radomska, M | 1 |
| Yui, K | 1 |
| Brown, R; Lo, R | 1 |
| Douglas, SD; Guo, CJ; Ho, WZ; Li, Y; Tian, S; Wang, X | 1 |
| Stimmel, B | 1 |
| Heilig, M | 2 |
| Asplund, K; Jonsson, E | 1 |
| Dhopesh, V; Fudala, PJ; Yu, E | 1 |
| Alvarez, CE; Bascarán, MT; Bobes, J; Brewer, C; Carreño, JE; San Narciso, GI; Sánchez del Río, J | 1 |
| Stephenson, J | 1 |
| de Kan, R; Geerlings, PJ; Kerkhof, BJ; Roozen, HG; van den Brink, W | 1 |
| Butelman, E; Kreek, MJ; LaForge, KS | 1 |
| Bisaga, A; Foltin, RW; Haney, M | 1 |
| Church, SH; Collins, E; Kleber, HD; Nunes, EV; Rothenberg, JL; Seracini, A; Sullivan, MA | 1 |
| Holtzman, SG | 1 |
| Borgland, SL; Christie, MJ; Connor, M; Furness, JB; Osborne, PB | 1 |
| Kerkhof, AJ; Roozen, HG; van den Brink, W | 1 |
| Barrett, AC; Picker, MJ; Smith, ES | 1 |
| Compton, M; Ling, W; Rawson, RA | 1 |
| Buonanno, A; De Risio, S; Gottheil, E; Mannelli, P | 1 |
| Arbuck, DM; Cruciani, RA; Lussier, D; Miller-Saultz, D | 1 |
| Colker, AC | 1 |
| Ahmadi, J; Ahmadi, K; Ohaeri, J | 1 |
| Aksel'rod, BA; Chichenkov, TO; Kubarev, DA; Savchenkov, VA; Sivolap, I | 1 |
| Alvarez, CE; Bascarán, MT; Bobes, J; Carreño, JE; Díaz, M; Narciso, GI | 1 |
| Digiusto, E; Mattick, RP; O'Brien, S; Ritter, A; Shakeshaft, A | 1 |
| Golden, SA; Sakhrani, DL | 1 |
| Arnold-Reed, DE; Hulse, GK; O'Neil, G | 1 |
| Freye, E; Levy, JV; Partecke, L | 1 |
| Beaini, AY; Carr, MP; Firth, AY; Pulling, S | 1 |
| Bailey, KP | 1 |
| Ali, R; Bell, J; Breen, C; Digiusto, E; Kimber, J; Lintzeris, N; Mattick, RP; Saunders, JB | 1 |
| Ali, R; Bell, J; Digiusto, E; Doran, CM; Gilmour, S; Lintzeris, N; Mattick, RP; Saunders, JB; Shanahan, MD; White, J | 1 |
| Antonilli, L; Badiani, A; Caprioli, D; Nencini, P; Petecchia, E | 1 |
| Gölz, J; Grüsser, SM; Partecke, G; Platz, W; Thalemann, CN | 1 |
| Cropsey, KL; St Clair, CL; Villalobos, GC | 1 |
| Comer, SD; Dackis, C; Kampman, K; Kleber, HD; O'Brien, CP; Rothenberg, JL; Sullivan, MA; Yu, E | 1 |
| Connor, JP; Dean, AJ; Jones, RT; Lawford, BR; Saunders, JB; Young, RM | 1 |
| Cubells, JF; Tang, YL; Zhao, C; Zhao, D | 1 |
| Ng, BY; Peh, LH | 1 |
| Haney, M | 1 |
| Besson, J; Camarasa, X; Khazaal, Y; Zullino, DF | 1 |
| Stancliff, S | 1 |
| Brady, KT | 1 |
| Bluschke, SM; De Jong, CA; Dijkstra, BA; Krabbe, PF; van der Staak, CP | 1 |
| Degenhardt, LJ; Gibson, AE | 1 |
| Kreek, MJ; Novick, DM | 1 |
| Petry, N; Stitzer, M | 1 |
| Gardner, TJ; Kosten, TR | 1 |
| Hulse, GK; Ngo, HT; Tait, RJ | 3 |
| Greenwald, MK | 1 |
| Saitz, R | 1 |
| O'Brien, CP | 2 |
| Casadonte, PP; Horton, T; Kolodner, GF; McMurphy, SM | 1 |
| Amirshahrokhi, K; Dehpour, AR; Ghazi-Khansari, M; Hadjati, J; Sotoudeh, M | 1 |
| Gorelick, DA; Gottheil, E; Mannelli, P; Patkar, AA; Peindl, K; Wu, LT | 1 |
| Lee, SS; Merican, MI; Noordin, NM; Rahman, HA; Ramly, R | 1 |
| Dolan, K; Larney, S | 1 |
| Newman, RG | 1 |
| Philibin, SD; Porter, JH; Vann, RE; Varvel, SA; Walentiny, DM; Wise, LE | 1 |
| Baud, FJ; Chevillard, L; Mégarbane, B; Risède, P | 1 |
| Gross, ER; Gross, GJ; Hsu, AK | 1 |
| Bramness, J; Gossop, M; Lobmaier, P; Waal, H | 1 |
| Lemesle, F; Nicola, W; Pierre Jonville-Béra, A | 1 |
| Abbott, PJ | 1 |
| Howland, RH | 1 |
| Gossop, M; Katevoll, T; Kunøe, N; Lobmaier, PP; Waal, H | 1 |
| Amato, L; Bargagli, AM; Davoli, M; Diecidue, R; Faggiano, F; Jarre, P; Perucci, CA; Salamina, G; Schifano, P; Vigna-Taglianti, F | 1 |
| Holt, E | 1 |
| Metzger, DS; Zhang, Y | 1 |
| Krupitsky, E; O'Brien, CP; Woody, GE; Zvartau, E | 1 |
| Amar, R; Casarella, J; Drexler, K; Fareed, A; Vayalapalli, S | 1 |
| Goldman, D; Heinz, A; Ho, MK; Kaprio, J; Kreek, MJ; Li, MD; Munafò, MR; Tyndale, RF | 1 |
| Milan-Lobo, L; Whistler, JL | 1 |
| Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Tharwani, HM; Wu, LT | 1 |
| Dodrill, CL; Helmer, DA; Kosten, TR | 1 |
| Law, F; Melichar, J; O'Shea, J | 1 |
| Craft, RM; Wakley, AA | 1 |
| Morgan, RW; Nicholson, KL | 1 |
| Bart, G | 2 |
| Metzger, DS; Woody, GE | 1 |
| Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Wu, LT | 1 |
| Flynn, PM; Friedmann, PD; Frisman, LK; Gordon, M; Hall, E; Hoskinson, R; Kinlock, T; Knight, K; Knudsen, HK; O'Connell, DJ; Sacks, S; Schwartz, R; Shafer, MS; Stein, LA; Welsh, WN | 1 |
| Bhatia, KS; Lee, T; Mannelli, P; Peindl, KS; Wu, LT | 1 |
| Bisaga, A; Kosten, T; Nunes, EV; O'Connor, PG; Sigmon, SC; Woody, G | 1 |
| Chisolm, MS; Jansson, LM; Jones, HE; Terplan, M | 1 |
| Jovanović, T; Lazarević, D; Nikolić, G | 1 |
| Banks, ML; Lunzer, MM; Negus, SS; Portoghese, PS; Rice, KC; Yekkirala, AS | 1 |
| Law, F; Melichar, J; O'Shea, J; Praveen, KT | 1 |
| Banks, ML; Negus, SS | 1 |
| Stitzer, ML | 1 |
| White, J | 1 |
| Bennett, L; Donaldson, LF; Green, A; Kaul, A; Melichar, JK; Mullings, EL; Munafò, MR; Nutt, DJ; O'Shea, J; Sharma, E | 1 |
| Hulse, GK; Reece, AS | 1 |
| Ingram, SL; Lamberts, JT; Li, MH; Neubig, RR; Smith, CE; Traynor, JR | 1 |
| Aghabiklooei, A; Ghoochani, A; Hassanian-Moghaddam, H; Mashayekhian, M; Nasouhi, S; Rahimi, M; Shadnia, S; Zamani, N | 1 |
| Duffy, S; Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; McCool, R; Neilson, M; Perry, AE | 1 |
| Matthew-Simmons, F; Ritter, A | 1 |
| Hoffman, RS; Kessler, BD | 1 |
| Gregg, M; Martinez, L; Samaritan, G | 1 |
| Bawor, M; Bonner, A; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Naji, L; Pare, G; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A | 1 |
| Friedmann, PD; Park, TW | 1 |
| Degenhardt, L; Farrell, M; Hall, W; Kimber, J; Larney, S | 1 |
| Fürst, Z; Hosztafi, S | 1 |
| Chatterjee, D; Jackson, H; Johnson, K; Mandell, K; Vanness, DJ | 1 |
| Aghabiklooei, A; Hassanian-Moghaddam, H; Zamani, N | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Lu, Z; Majumdar, S; Pan, YX; Pasternak, GW; Rossi, GC; Xu, J | 1 |
| Glanville, JM; Godfrey, C; Hewitt, C; Martyn-St James, M; Neilson, M; Perry, AE; Woodhouse, R | 1 |
| Donnerstag, N; Lüthi, A; Mehlig, A; Raetz Bravo, A; Schneider, T; Taegtmeyer, A | 1 |
| Maremmani, AG; Maremmani, I; Parrino, MW; Samuels, PN | 1 |
| Dahmke, H; Kullak-Ublick, GA; Kupferschmidt, H; Weiler, S | 1 |
| Cucciare, MA; Garrison-Diehn, C; Schultz, NR; Timko, C; Vittorio, L | 1 |
| Binswanger, I; Blue-Howells, J; Clark, S; Finlay, AK; Frayne, SM; Harris, AH; McGuire, J; Oliva, E; Rosenthal, J; Smelson, D; Timko, C | 1 |
| Bonilla, W; Flannery, M; Goldfeld, K; Gourevitch, MN; Johnson, CW; Laska, E; Lee, JD; Leibowitz, N; McDonald, RD; Rotrosen, J; Santana-Correa, N; Tofighi, B | 1 |
| Bennett, D; Chandler, RK; Condon, T; Dunlap, LJ; Farabee, D; Finger, MS; Hillhouse, M; Kelly, SM; Laska, E; Lee, JD; McCollister, K; McDonald, RD; Mitchell, SG; O'Grady, KE; Schwartz, RP; Zarkin, GA | 1 |
| Cabrera, EA; Lindgren, E; Miller, G; Volkow, ND; Wang, GJ; Wiers, CE | 1 |
| Anderson, B; Bailey, G; Herman, D; Stein, M; Uebelacker, LA | 1 |
| Klein, JW | 1 |
| Ayanga, D; Kosten, TR; Shorter, D | 1 |
| Alagoz, E; Gustafson, DH; Johnson, RA; Kornfield, R; Landucci, G; Mares, ML; McTavish, F; Pe-Romashko, K; Quanbeck, A; Shah, D; Thomas, C; Westergaard, RP | 1 |
| Gryczynski, J; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A | 1 |
| Hulse, G; Kelty, E | 4 |
| Griffin, BL; Stone, RH; Todd, TJ; Tran, TH; Vest, KM | 1 |
| Chang, DC; Fairbairn, N; Klimas, J; Wood, E | 1 |
| Desai, N; Kelly, MM; Quiñones, T; Reilly, E; Rosenheck, R | 1 |
| Bagley, SM; Carney, BL; Hadland, SE | 1 |
| Atreja, N; Duncan, M; Gore, M; Shah, A; Tai, KS | 1 |
| Baijnath, S; Gopal, ND; Govender, T; Kruger, HG; Naicker, T; Pamreddy, A; Teklezgi, BG | 1 |
| Alexander-Scott, N; Boss, R; Brinkley-Rubinstein, L; Clarke, J; Green, TC; Marshall, BDL; Rich, JD | 1 |
| Azhar, G; Chen, C; Hempel, S; Maglione, MA; Maksabedian, E; Newberry, S; Raaen, L; Shahidinia, N; Shanman, RM; Shen, M | 1 |
| Graham, DP; Kosten, TR; Nielsen, DA | 1 |
| Quaye, AN; Ward, EN; Wilens, TE | 1 |
| Bisaga, A; Campbell, AN; Crystal, S; Friedmann, PD; Johnson, KA; Levin, FR; Nunes, EV; Olfson, M; Pincus, HA; Remien, RH; Williams, AR | 1 |
| Bagley, SM; Bernson, D; Land, T; Larochelle, MR; Liebschutz, JM; Stopka, TJ; Walley, AY; Wang, N; Xuan, Z | 1 |
| Bao, YP; Blow, FC; Degenhardt, L; Farrell, M; Ilgen, M; Li, JQ; Liu, MX; Lu, L; Ma, J; Shi, J; Su, MF; Wang, RJ | 1 |
| Alexander, GC; Saloner, B; Stoller, KB | 1 |
| Blackney, KA; Edwards, DA; Kamdar, NV; Liu, CA | 1 |
| Cotton, A; Elton, P; Irving, P; Jones, S; McNeill, J; Mohammed, F; Monk, R; Murphy, PN; Sharples, L; Wareing, M | 1 |
| Aschenbrenner, DS | 1 |
| Binswanger, IA; Fazel, S; Hellner, C; Larsson, H; Molero, Y; Zetterqvist, J | 1 |
| Aggarwal, AK; Harrison, TK; Kornfeld, H; Lembke, A | 1 |
| Haffajee, RL; Weintraub, E; Yang, YT | 1 |
| Fauconneau, B; Favrelière, S; Lafay-Chebassier, C; Montastruc, F; Pérault-Pochat, MC; Quillet, A; Yéléhé-Okouma, M | 1 |
| Clarke, JG; Gresko, SA; Martin, RA; Rich, JD | 1 |
| Bagley, SM; Hadland, SE; Larochelle, MR; Levy, S; Rodean, J; Samet, JH; Silverstein, M; Zima, BT | 1 |
| Broglio, K; Matzo, M | 1 |
| Dehpour, AR; Fakhraei, N; Hashemizadeh, S; Javadian, N; Nili, F; Rahimi, N; Rahimian, R | 1 |
| Binswanger, IA; Bowe, T; Finlay, AK; Harris, AHS; Smelson, D; Stimmel, MA; Timko, C; Yu, M | 1 |
| Gordon, MS; Gryczynski, J; Jaffe, JH; Kelly, SM; Mitchell, MM; Mitchell, SG; O'Grady, KE; Schwartz, RP | 1 |
| Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, A; Schmidt, EM; Timko, C; Wong, JJ | 1 |
| Kaplan, L | 1 |
| Ali, R; Hu, L; Marsden, J; Rush, AJ; Tai, B; Volkow, N | 1 |
| Fanucchi, L; Korthuis, PT; Springer, SA | 1 |
| McKee, SA; Moore, KE; Oberleitner, LMS; Reid, HH; Roberts, W; Smith, KMZ | 1 |
| Heller, NM; Maher, DP; Walia, D | 1 |
| Butler, F; Witt, L | 1 |
| Hulse, G; Joyce, D; Kelty, E | 1 |
| Barnett, BS; Suzuki, J; Ward, HB | 1 |
| Barnes, DE; Marton, T; Wallace, A; Woolley, JD | 1 |
| Barry, CL; Gollust, SE; Kennedy-Hendricks, A; Levin, J; McGinty, EE; Stone, E | 1 |
| Rosenberg, L | 1 |
| Aghaei, I; Bahramnejad, E; Dehpour, AR; Kazemi Roodsari, S; Rahimi, N | 1 |
| Landau, R | 1 |
| Dzau, VJ; Leshner, AI | 1 |
| Duello, A; Green, L; Horn, P; Presnall, N; Rudder, T; Stringfellow, E; Winograd, RP; Wood, C | 1 |
| Allan, GM; Dugré, N; Finley, CR; Garrison, S; Kolber, MR; Korownyk, C; Lindblad, AJ; Perry, D; Thomas, B; Ting, R; Ton, J; Vandermeer, B; Yang, PR | 1 |
| Banken, R; Kumar, VM; Otuonye, IS; Pearson, SD | 1 |
| Choi, S; Healy, S; Neighbors, CJ; Shapoval, L; Sun, T; Yerneni, R | 1 |
| Glance, JB; Gopalan, P; Kmiec, J; Spada, M | 1 |
| Bridgeman, PJ; Koehl, JL; Zimmerman, DE | 1 |
| Katz, E; Towers, CV; Visconti, K; Weitz, B | 1 |
| Lin, MP; Manini, AF; Richardson, LD; Shastry, S | 1 |
| Bell, J; Strang, J | 1 |
| Chemi, C; Dickson, V; Lee, JD; Suhail-Sindhu, S; Tofighi, B; Williams, AR | 1 |
| Camenga, DR; Colon-Rivera, HA; Muvvala, SB | 1 |
| Alam, F; Dhadley, S; Roberts, P; Townley, J; Webster, R; Wright, N | 1 |
| Gold, MS; Oesterle, TS; Rummans, TA; Thusius, NJ | 1 |
| Ashford, RD; Bergman, BG; Kelly, JF | 1 |
| Badolato, R; Flannery, M; Garment, AR; Giftos, J; Lee, JD; McDonald, RD; Tofighi, B; Velasquez, M; Vittitow, A | 1 |
| Coffa, D; Snyder, H | 1 |
| Bagley, SM; Bernson, D; Hadland, SE; Land, T; Larochelle, MR; Patel, A; Samet, JH; Silverstein, M; Walley, AY; Wang, N; Xuan, Z | 1 |
| Byrd, DJ; Campbell, TB; Clarke, TJ; Jones, CM; McCance-Katz, EF; Ohuoha, C | 1 |
| Brown, JN; Elias, AM; Pepin, MJ | 1 |
| Blanco, C; Volkow, ND | 1 |
| Brezel, ER; Fox, AD; Powell, T | 1 |
| Felix, C; Olsen, Y; Sharfstein, JM | 1 |
| Johnson, JA; Liebschutz, JW; Martin, B; Montgomery, MW; Mosquera, M; Price, CD; Robinson, D; Schnipper, JL; Solomon, DA; Suzuki, J; Weiss, RD | 1 |
| Banks, ML; Negus, SS; Townsend, EA | 1 |
| Bergeria, CL; Dunn, KE; Hobelmann, JG; Huhn, AS; Oyler, GA; Strickland, JC; Umbricht, A | 1 |
| Agus, D; Fingerhood, M; Krawczyk, N; Lyons, BC; Mojtabai, R; Saloner, B; Stuart, EA; Weiner, JP | 1 |
| Babakhanlou-Chase, H; Bernson, D; Land, T; Larochelle, MR; Li, Y; Lodi, S; Walley, AY | 1 |
| Fuehrlein, B; Jaeger, S | 1 |
| Hulse, G; Joyce, D; Kelty, E; Preen, DB | 1 |
| Altice, FL; Bromberg, DJ; Nyhan, K; Refsland, BM; Stanojlović, M; Viera, A; Whittaker, S | 1 |
| Wakeman, SE | 1 |
| Andraka-Christou, B; Atkins, D; Madeira, J; Silverman, RD | 1 |
| Fine, M; Herscher, M; Hirt, L; Navalurkar, R; Wang, L | 1 |
| Burden, J; Codell, NK; Drexler, K; Dungan, MT; Gordon, AJ; Hagedorn, H; Hawkins, EJ; Mhatre-Owens, A | 1 |
| Joo, H; KuKanich, B; KuKanich, K; Locuson, CW; Rankin, DC | 1 |
| Chalhoub, RM; Kalivas, PW | 1 |
| Bachhuber, MA; Barry, CL; Kennedy-Hendricks, A; McGinty, EE; Stone, E | 1 |
| Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z | 1 |
| Ameli, O; Azocar, F; Chaisson, CE; Crown, WH; Larochelle, MR; McPheeters, JT; Sanghavi, DM; Wakeman, SE | 1 |
| Ayers, C; Chan, B; Freeman, M; Kansagara, D; Kondo, K; Korthuis, PT; Paynter, R | 1 |
| Andraka-Christou, B; Attermann, J; Beck, AJ; Buche, J; Cupito, A; Haffajee, RL | 1 |
| Andraka-Christou, B; Atkins, D | 1 |
| Berke, K; Cho, P; Comroe, A; Crauer, B; Fitzgerald, AH; Gonzalez, SE; Jensen, G; Klocke, EE; Komp, M; KuKanich, B; KuKanich, K; Mason, D; Orchard, R; Rankin, DC; Upchurch, DA | 1 |
| Biondi, BE; Cioe, K; Easly, R; Simard, A; Springer, SA; Zheng, X | 1 |
| Allen, J; Beauchamp, GA; Boateng, N; Burmeister, DB; Esposito, SB; Laubach, LT; Lauber, P; Roth, P; Shaak, S; Yazdanyar, A | 1 |
| Baron, CA; Blinova, K; Johannesen, L; Patel, D; Randolph, AL; Ren, M; Sheng, J; Strauss, DG; Thiebaud, N; Tran, PN; Volpe, DA; Wu, M; Wu, WW | 1 |
| Donelan, CJ; Evans, EA; Hayes, E; Potee, RA; Schwartz, L | 1 |
| Farnaghi, F; Gholami, N; Hassanian-Moghaddam, H; McDonald, R; Saberi, M; Zamani, N | 1 |
| Crawford, TN; Fischer, KB; Gainer, DM; Wright, MD | 1 |
| Basaraba, C; Bisaga, A; Brooks, DJ; Choi, CJ; Levin, FR; Mahony, AL; Mariani, JJ; Naqvi, N; Pavlicova, M | 1 |
| Baratta, JL; Ferd, P; Patel, N; Schwenk, ES; Torjman, MC; Viscusi, ER | 1 |
| Bhat, NR; Bierut, LJ; Borodovsky, JT; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 1 |
| Cho, P; Fitzgerald, AH; Komp, MS; KuKanich, B; KuKanich, K; Locuson, CW; Rankin, DC | 1 |
| Bergeria, CL; Dunn, KE; Huhn, AS; Nayak, SM; Strain, EC | 1 |
| Adekoya, P; Gulati, A; Hunter, C; Jones, MR; Kaye, AD; Kaye, AM; Kuppalli, S; Orhurhu, V; Seth, R; Urits, I | 1 |
| Bachireddy, C; Terplan, M | 1 |
| Freeman, PR; Huang, Z; Oser, C; Sohn, M; Talbert, JC | 1 |
| Campbell, ANC; Choo, TH; Haenlein, P; Lee, JD; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, J; Shulman, M; Tofighi, B; Wai, J | 1 |
| Ahmed, S; Galbis-Reig, D; Hybki, B; Penders, T; Stanciu, C | 1 |
| Bain, PA; Carrero, ND; Chatterjee, A; Li, R; McLaughlin, MF | 1 |
| Assoumou, SA; Barocas, J; Chatterjee, A; Hadland, SE; Linas, BP; Morgan, JR; Murphy, SM; Walley, AY | 1 |
| Adam, GP; Balk, EM; Becker, SJ; Danko, KJ; Helseth, SA; Saldanha, IJ; Scott, K; Steele, DW | 1 |
| Cao, DN; Li, F; Li, J; Wu, N | 1 |
| Bandara, S; Barry, CL; Kennedy-Hendricks, A; Merritt, S; Saloner, B | 1 |
| Nalven, T; Schick, MR; Spillane, NS; Weyandt, LL | 1 |
| Bierut, LJ; Grucza, RA; Hartz, SM; Mintz, CM; Presnall, NJ; Sahrmann, JM; Xu, KY | 1 |
| Ahrens, K; Allen, L; Austin, A; Barnes, AJ; Burns, M; Chang, CH; Clark, S; Cole, E; Crane, D; Cunningham, P; Donohue, JM; Gordon, AJ; Idala, D; Jarlenski, MP; Junker, S; Kennedy, S; Kim, JY; Lanier, P; Mauk, R; McDuffie, MJ; Mohamoud, S; Pauly, N; Sheets, L; Talbert, J; Tang, L; Zivin, K | 1 |
| Kalin, NH | 1 |
| Komrowski, MD; Sekhri, NK | 1 |
| Light, T; Madden, EF; Prevedel, S; Sulzer, SH | 1 |
| Hochheimer, M; Unick, GJ | 1 |
| Allen, LR; Manini, AF; Nobel, I; Richardson, LD; Shastry, S; Vidal, K | 1 |
| Laks, J; Peterkin, A; Weinstein, ZM | 1 |
| Bromberg, DJ; Karamouzian, M; Pilarinos, A | 1 |
| Ashmead, R; Bailey, E; Bickert, T; Bonny, AE; Doogan, NJ; Mack, A; Schmidt, S; Tossone, K; Zhang, P | 1 |
| Chaisson, CE; Ciemins, E; LaRochelle, MR; Linas, BP; Morgan, JR; Quinn, EK; Stempniewicz, N; Walley, AY; White, LF | 1 |
| Amaducci, AM; Beauchamp, GA; Hanisak, JL; Koons, AL; Laskosky, J; Maron, BM; McLoughlin, TM | 1 |
| Fradkin, D; Kameg, B; Lepore, M | 1 |
| Beck, M; Kay, A; Shmuts, R | 1 |
| Digbeu, B; Kuo, YF; Priyadarshni, S; Raji, MA; Yu, X | 1 |
| Anderson-Harper, R; Duello, A; Gochez-Kerr, T; Lohmann, B; Miles, J; Richardson, K; Winograd, RP; Wood, CA | 1 |
| Biondi, BE; Schlossberg, EF; Shaw, A; Springer, SA; Vander Wyk, B | 1 |
| Dromgoole, D; Ghanem, N; Hussein, A; Jermyn, RT | 1 |
| Douros, A; Farhat, I; Lim, J; Panagiotoglou, D | 1 |
| Anguiano, V; Joudrey, PJ; Kolak, M; Lin, Q; Paykin, S; Wang, EA | 1 |
| Anselin, L; Kolak, M; Lin, Q; Pollack, H; Schneider, J; Taylor, B; Watts, B | 1 |
| Bierut, LJ; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 1 |
| Angermaier, G; Carswell, N; Castaneda, C; Delgado, F | 1 |
| Abare, M; Chyorny, A; Olson, M; Wilhelm-Leen, E; Will, J | 1 |
| Berro, LF; Freeman, KB; Rowlett, JK; Talley, JT; Zamarripa, CA | 1 |
| Abdel-Mohsen, M; Azzoni, L; Fair, M; Giron, LB; Hiserodt, E; Lalley-Chareczko, L; Lynn, K; Montaner, LJ; Mounzer, K; Trooskin, S; Vadrevu, S; Zhao, L | 1 |
| Andraka-Christou, B; Buche, J; Haffajee, RL; Page, C; Schoebel, V | 1 |
| Di Paola, A; Lier, AJ; Seval, N; Springer, SA; Vander Wyk, B | 1 |
| Agius, E; Kollin, R; Lee, G; Madden, EF; Pasman, E; Resko, SM; Rodriguez, B | 1 |
| Blanco, C; Compton, WM; Hodges, K; Jones, CM; Ling, SM; Losby, JL; Shoff, C | 1 |
| Bolton, J; Hoang, H; Laiteerapong, N; Marsh, J; Murugesan, M; Nocon, R; Peterson, L; Pollack, H | 1 |
| Acuña, AM; Leyrer-Jackson, JM; Olive, MF | 1 |
| Cheng, A; Garrity, K; Hey, SP; Lee, JD; Lindquist, K; Malone, M; McDonald, R; McNeely, J; Pace, N; Roberts, T; Schatz, D; Sugarman, A; Tofighi, B; Vittitow, A; Williams, O | 1 |
| Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Williams, NT | 1 |
| Batki, SL; Baxley, C; Becker, W; Borsari, B; Herbst, E; Manuel, JK; Pennington, D; Reavis, JV; Seal, K | 1 |
| Konakanchi, JS; Sethi, R | 1 |
| Balise, RR; Brandt, L; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Odom, GJ | 1 |
| Bisaga, A; Dresser, L; Fishman, M; Ghitza, UE; Greiner, MG; Hamilton, A; Hefner, K; Ho, R; Jelstrom, E; Nunes, EV; Opara, O; Potter, K; Rotrosen, J; Scheele, C; Shulman, M; Tafessu, HM; Voronca, DC | 1 |
| Batty, E; Booty, MD; Harp, K; Knudsen, HK; Oser, CB; Staton, M | 1 |
| Cox, KM; Doyle, M; Marsch, LA; McLeman, BM; Murray, OB; Ryer, J; Saunders, EC; Watts, D | 1 |
| Cornett, EM; Edinoff, AN; Flanagan, CJ; Jackson, ED; Kaye, AD; Kaye, AM; Pearl, NZ; Sinnathamby, ES; Wenger, DM | 1 |
| Haigney, MCP; Kao, DP; Kleiman, RB; Klein, M; Krantz, MJ; Rudo, TJ; Stockbridge, N | 1 |
| Berger, NA; Davis, PB; Kaelber, DC; Volkow, ND; Wang, L; Xu, R | 1 |
| Balise, RR; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Rotrosen, J; Saxon, AJ; Weiss, RD | 1 |
107 review(s) available for methadone and naltrexone
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[The treatment of drug-dependence (author's transl)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Alcoholism; Amphetamines; Barbiturates; Communication; Drug Tolerance; Female; Halfway Houses; Humans; Male; Methadone; Middle Aged; Morphine Dependence; Motivation; Naltrexone; Personality Disorders; Psychotherapy; Social Control, Formal; Social Control, Informal; Substance-Related Disorders | 1978 |
Methadone maintenance and narcotic blocking drugs. Appendix.
Topics: Administration, Oral; Cyclazocine; Drug Tolerance; Heroin Dependence; Humans; Injections, Subcutaneous; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Research; Substance Withdrawal Syndrome | 1977 |
Disposition of narcotics and narcotic antagonists.
Topics: Animals; Biotransformation; Chickens; Dogs; Guinea Pigs; Haplorhini; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics; Pupil; Rabbits; Rats; Time Factors | 1976 |
[Clonidine-naltrexone: a new technic for the detoxification of opiate addicts].
Topics: Clonidine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1990 |
Drugs of abuse--opiates.
Topics: Central Nervous System; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotics; Opioid-Related Disorders; Primary Health Care; Receptors, Opioid | 1990 |
Clinical toxicology of drugs used in the treatment of opiate dependency.
Topics: Buprenorphine; Clonidine; Humans; Methadone; Methadyl Acetate; Naltrexone; Opioid-Related Disorders | 1990 |
Clonidine and the treatment of the opiate withdrawal syndrome.
Topics: Clonidine; Humans; Hypotension; Methadone; Naltrexone; Narcotics; Substance Withdrawal Syndrome | 1988 |
Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory.
Topics: Adrenergic Fibers; Animals; Antidepressive Agents, Tricyclic; Brain; Clinical Trials as Topic; Clonidine; Dextropropoxyphene; Drug Therapy, Combination; Heroin Dependence; Humans; Locus Coeruleus; Methadone; Morphine; Naltrexone; Narcotics; Norepinephrine; Rats; Substance Withdrawal Syndrome | 1986 |
Behavioral pharmacology of buprenorphine.
Topics: Adult; Animals; Buprenorphine; Conditioning, Operant; Eating; Heroin Dependence; Humans; Macaca; Male; Methadone; Morphinans; Naltrexone; Opioid-Related Disorders; Reinforcement, Psychology; Self Administration | 1985 |
[Narcotic withdrawal syndrome. Therapeutic methods].
Topics: Acupuncture Therapy; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Analgesia; Brain; Central Nervous System Agents; Clonidine; Endorphins; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Receptors, Opioid; Substance Withdrawal Syndrome; Substance-Related Disorders | 1982 |
The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
Topics: Clinical Trials as Topic; Double-Blind Method; Endorphins; Humans; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1980 |
New insights and treatments: opiate withdrawal and cocaine addiction.
Topics: Brain Chemistry; Clonidine; Cocaine; Dopamine; Humans; Methadone; Naltrexone; Norepinephrine; Substance Withdrawal Syndrome; Substance-Related Disorders | 1984 |
Managing illicit drug use. A practical guide.
Topics: Buprenorphine; Counseling; Disulfiram; Humans; Methadone; Methadyl Acetate; Naltrexone; Psychotherapy; Self-Help Groups; Substance Abuse Treatment Centers; Substance-Related Disorders | 1994 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Psychiatric Status Rating Scales; Receptors, Opioid; Substance Withdrawal Syndrome | 1993 |
Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.
Topics: Animals; Buprenorphine; Clonidine; Humans; Locus Coeruleus; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1993 |
What is important in drug misuse treatment?
Topics: Buprenorphine; Clonidine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders; United Kingdom | 1996 |
[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
Topics: Alcoholism; Delayed-Action Preparations; Follow-Up Studies; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Treatment Outcome | 1996 |
Role of maintenance treatment in opioid dependence.
Topics: Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disorders | 1999 |
Pharmacologic treatment of heroin-dependent patients.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Heroin Dependence; Humans; Mental Disorders; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Physician's Role; Substance Withdrawal Syndrome | 2000 |
Safe approaches to treating drug addiction.
Topics: Drug Overdose; Family Practice; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Sorption Detoxification; Substance-Related Disorders | 2000 |
[Contemporary methods in pharmacotherapy in the opiate dependent treatment].
Topics: Adrenergic alpha-Agonists; Buprenorphine; Clonidine; Heroin Dependence; Humans; Inactivation, Metabolic; Methadone; Naltrexone; Narcotic Antagonists; Narcotics | 2000 |
The physical and psychosocial consequences of opioid addiction: an overview of changes in opioid treatment.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2000 |
Pharmacotherapy of addictions.
Topics: Alcoholism; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance-Related Disorders | 2002 |
Pharmacologic treatments for heroin and cocaine dependence.
Topics: Buprenorphine; Clonidine; Cocaine-Related Disorders; Comorbidity; Heroin Dependence; Humans; Mental Disorders; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics | 2003 |
Behavioral health issue brief: pharmacotherapy treatment of alcoholism and drug addiction: overview and bibliography: year end report-2002.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Buprenorphine; Drug Therapy; Humans; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Substance-Related Disorders; United States | 2002 |
Pharmacological treatments for substance use disorders.
Topics: Adrenergic beta-Antagonists; Alcohol Deterrents; Anti-Anxiety Agents; Benzodiazepines; Buprenorphine; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neurobiology; Neuropharmacology; Psychopharmacology; Substance Withdrawal Syndrome; Substance-Related Disorders | 2004 |
Pharmacotherapy treatment in substance-dependent correctional populations: a review.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Prisoners; Substance-Related Disorders | 2005 |
Opiate addiction in China: current situation and treatments.
Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse, Intravenous; Substance Withdrawal Syndrome; Sympatholytics | 2006 |
Contingency management for treatment of substance abuse.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Counseling; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Patient Compliance; Reinforcement, Psychology; Substance-Related Disorders; Token Economy; Treatment Outcome | 2006 |
Treatment of alcohol and other drug dependence.
Topics: Alcoholism; Behavior, Addictive; Comorbidity; Humans; Methadone; Naltrexone; Psychotherapy; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome | 2007 |
A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care?
Topics: Buprenorphine; Heroin Dependence; HIV Infections; Humans; International Cooperation; Methadone; Naltrexone; Narcotic Antagonists; Patient Care; Prisoners; Prisons | 2009 |
The pharmacological treatment of opioid addiction--a clinical perspective.
Topics: Adrenergic Agonists; Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Social Support; Substance Withdrawal Syndrome | 2010 |
A review of the community reinforcement approach in the treatment of opioid dependence.
Topics: Adult; Female; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Psychotherapy; Reinforcement, Psychology; Therapy, Computer-Assisted | 2009 |
Drug treatment as HIV prevention: expanding treatment options.
Topics: Alcoholism; Buprenorphine; Clinical Protocols; Drug Users; Health Promotion; HIV Infections; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Risk Reduction Behavior; Risk-Taking; Substance Abuse, Intravenous; Substance-Related Disorders | 2010 |
Heroin anticraving medications: a systematic review.
Topics: Buprenorphine; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2010 |
Breaking barriers in the genomics and pharmacogenetics of drug addiction.
Topics: Genetic Testing; Genetic Variation; Genomics; Humans; Methadone; Naltrexone; Pharmacogenetics; Substance-Related Disorders | 2010 |
Prescription pain medication dependence.
Topics: Analgesics; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pain; Prescription Drugs; Substance-Related Disorders | 2011 |
Opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Evidence-Based Medicine; Heroin Dependence; Humans; Incidence; Methadone; Naltrexone; Opioid-Related Disorders | 2009 |
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
Topics: Biological Availability; Buprenorphine; Chemistry, Pharmaceutical; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clinical Protocols; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Maintenance medication for opiate addiction: the foundation of recovery.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Long-Term Care; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2012 |
Medications development for opioid abuse.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Endocannabinoids; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neuroglia; Opioid-Related Disorders; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome | 2013 |
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2013 |
Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders.
Topics: Acamprosate; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Directive Counseling; Disulfiram; Humans; Methadone; Naltrexone; Narcotic Antagonists; Practice Patterns, Physicians'; Substance-Related Disorders; Taurine; United States | 2014 |
[Therapy in heroin addiction].
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Buprenorphine; Euphoria; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment | 2014 |
Pharmacological interventions for drug-using offenders.
Topics: Adult; Buprenorphine; Crime; Criminals; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotics; Opiate Substitution Treatment; Randomized Controlled Trials as Topic; Substance-Related Disorders | 2015 |
Retention in medication-assisted treatment for opiate dependence: A systematic review.
Topics: Behavior Therapy; Buprenorphine; Heroin; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2016 |
Neuroimaging the Effectiveness of Substance Use Disorder Treatments.
Topics: Clinical Trials as Topic; Cognitive Behavioral Therapy; Craving; Humans; Methadone; Naltrexone; Neurofeedback; Neuroimaging; Substance-Related Disorders; Treatment Outcome | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Update on pharmacotherapy for treatment of opioid use disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Combined Modality Therapy; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2016 |
Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2017 |
A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Drug Implants; Female; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies | 2017 |
Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Treatment Outcome | 2017 |
Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care | 2018 |
Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
Opioid Use Disorders: Perioperative Management of a Special Population.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Drug Tolerance; Humans; Interdisciplinary Communication; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Patient Discharge; Patient-Centered Care; Perioperative Care | 2018 |
Developing an opioid use disorder treatment cascade: A review of quality measures.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2018 |
Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk | 2019 |
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain Management; Perioperative Care | 2018 |
CE: Acute Pain Management for People with Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Nurse's Role; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Palliative Care; Substance Withdrawal Syndrome | 2018 |
Pharmacotherapy for opioid addiction in community corrections.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons | 2018 |
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Topics: Buprenorphine; HIV Infections; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Treatment Outcome | 2019 |
Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Randomized Controlled Trials as Topic; Recidivism; Risk-Taking | 2019 |
Medication Treatment For Substance Abuse.
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Patient Compliance; Patient Safety; Quality of Life; Risk Assessment; Severity of Illness Index; Substance-Related Disorders; Treatment Outcome; United States | 2019 |
Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery.
Topics: Analgesia, Patient-Controlled; Buprenorphine; Cesarean Section; Female; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain, Postoperative; Pregnancy; Pregnancy Complications | 2019 |
Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Randomized Controlled Trials as Topic; Systematic Reviews as Topic | 2019 |
A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
Topics: Analgesics, Opioid; Buprenorphine; Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Methadone; Models, Economic; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Policy; Treatment Outcome; United States | 2019 |
Consideration of opioid agonist treatment in a pregnant adolescent: A case report and literature review.
Topics: Adolescent; Ambulatory Care; Analgesics, Opioid; Buprenorphine; Child, Foster; Female; Humans; Lost to Follow-Up; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Pregnancy in Adolescence | 2020 |
Medications for management of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Medication Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
Topics: Adolescent; Adolescent Behavior; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Medication-Assisted Treatment for Opioid-Use Disorder.
Topics: Algorithms; Buprenorphine; Decision Trees; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Opioid Use Disorder: Medical Treatment Options.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Evidence-Based Medicine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2019 |
Adjunctive memantine for opioid use disorder treatment: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Outcome Assessment, Health Care; Substance Withdrawal Syndrome | 2019 |
Medications Development for Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Drug Development; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome | 2021 |
Buprenorphine initiation to treat opioid use disorder in emergency rooms.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2020 |
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Management | 2020 |
Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
Topics: Adolescent; Buprenorphine; Child; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2020 |
Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
Topics: Analgesics, Opioid; Buprenorphine; Harm Reduction; Hospitalization; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic | 2020 |
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Brain; Buprenorphine; Disease Models, Animal; Endocannabinoids; Glutamic Acid; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Orexins; Reward; Secondary Prevention; Signal Transduction; Treatment Outcome | 2020 |
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult | 2020 |
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.
Topics: Analgesics, Opioid; Antidepressive Agents; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Female; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Recent Advances in the Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Implants; Humans; Injections, Intramuscular; Methadone; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Receptors, G-Protein-Coupled; Receptors, Opioid, mu; Secologanin Tryptamine Alkaloids; Thiophenes; Urea; Vaccines | 2021 |
Pharmacotherapy for Management of 'Kratom Use Disorder': A Systematic Literature Review With Survey of Experts.
Topics: Buprenorphine; Humans; Methadone; Mitragyna; Naltrexone; Opioid-Related Disorders; United States | 2021 |
Opioid use disorder treatment for people experiencing homelessness: A scoping review.
Topics: Buprenorphine; Health Services Accessibility; Health Services Misuse; Humans; Ill-Housed Persons; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States; Young Adult | 2022 |
Insights into the mechanisms underlying opioid use disorder and potential treatment strategies.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2021 |
Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Child; Cross-Sectional Studies; Female; Humans; Male; Medicaid; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; United States; Young Adult | 2021 |
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Ethnicity; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2022 |
Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Disease Management; Drug Overdose; Female; Fentanyl; Harm Reduction; Humans; Male; Mental Disorders; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Practice Guidelines as Topic; Prevalence | 2022 |
Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Health Services Accessibility; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2022 |
An overview of buprenorphine prescribing for the advanced practice psychiatric nurse.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Review of medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; COVID-19; COVID-19 Drug Treatment; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Morphine; Naltrexone; Network Meta-Analysis; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2022 |
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Buprenorphine; Hospitals; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; United States | 2022 |
Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Opioid Use Disorder Treatments: An Evidence Map.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2023 |
The Growing Epidemic of Opioid Use Disorder in the Elderly and Its Treatment: A Review of the Literature.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Drug-Related Side Effects and Adverse Reactions; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain, Postoperative | 2023 |
47 trial(s) available for methadone and naltrexone
| Article | Year |
|---|---|
Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Heroin; Heroin Dependence; Humans; Male; Methadone; Motivation; Naloxone; Naltrexone; Patient Compliance; Placebos; Research Design; Social Adjustment | 1978 |
Naltrexone in methadone maintenance patients electing to become "drug free".
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Patient Dropouts; Research Design | 1976 |
Comments and findings from a naltrexone double blind study.
Topics: Clinical Trials as Topic; Humans; Methadone; Naloxone; Naltrexone; Research Design; Statistics as Topic; Substance-Related Disorders | 1976 |
Clinical experiences with naltrexone in 370 detoxified addicts.
Topics: Clinical Trials as Topic; Cyclazocine; Drug Administration Schedule; Humans; Methadone; Naloxone; Naltrexone; Patient Compliance; Physicians; Placebos; Research Personnel; Substance-Related Disorders | 1976 |
Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.
Topics: Adult; Blood Pressure; Buprenorphine; Double-Blind Method; Female; Humans; Male; Methadone; Methoxyhydroxyphenylglycol; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1992 |
Treatment of heroin addicts using buprenorphine.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Neurologic Examination; Substance Withdrawal Syndrome | 1991 |
Opioid antagonist challenges in buprenorphine maintained patients.
Topics: Administration, Sublingual; Adult; Buprenorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Infusions, Intravenous; Male; Methadone; Naloxone; Naltrexone; Substance Withdrawal Syndrome | 1990 |
Clonidine treatment of the opiate withdrawal syndrome. A review of clinical trials of a theory.
Topics: Adrenergic Fibers; Animals; Antidepressive Agents, Tricyclic; Brain; Clinical Trials as Topic; Clonidine; Dextropropoxyphene; Drug Therapy, Combination; Heroin Dependence; Humans; Locus Coeruleus; Methadone; Morphine; Naltrexone; Narcotics; Norepinephrine; Rats; Substance Withdrawal Syndrome | 1986 |
Clonidine versus methadone for opiate detoxification.
Topics: Clinical Trials as Topic; Clonidine; Humans; Inactivation, Metabolic; Methadone; Naltrexone; Opioid-Related Disorders | 1980 |
The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
Topics: Clinical Trials as Topic; Double-Blind Method; Endorphins; Humans; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1980 |
Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Outcome and Process Assessment, Health Care; Placebos; Substance Withdrawal Syndrome | 1983 |
Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity.
Topics: Adult; Blood Pressure; Brain; Female; Humans; Kinetics; Male; Methadone; Methoxyhydroxyphenylglycol; Naloxone; Naltrexone; Narcotics; Norepinephrine; Substance Withdrawal Syndrome; Substance-Related Disorders | 1984 |
Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy.
Topics: Adult; Blood Pressure; Clonidine; Double-Blind Method; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
Operant analysis of human heroin self-administration and the effects of naltrexone.
Topics: Adult; Conditioning, Operant; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Placebos; Self Administration | 1981 |
Buprenorphine for benzodiazepine-abusing heroin addicts.
Topics: Administration, Sublingual; Benzodiazepines; Buprenorphine; Heroin Dependence; Humans; Methadone; Naltrexone; Substance-Related Disorders | 1994 |
Assessment of nalmefene glucuronide as a selective gut opioid antagonist.
Topics: Adult; Arousal; Autonomic Nervous System; Constipation; Dose-Response Relationship, Drug; Gastrointestinal Motility; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1995 |
Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone.
Topics: Administration, Oral; Adult; Drug Compounding; Drug Stability; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome; Substance-Related Disorders | 1997 |
[Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection].
Topics: Adult; Female; Hepatitis C; Humans; Liver; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Necrosis; Prospective Studies; Substance Abuse, Intravenous; Transaminases | 1997 |
Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure.
Topics: Acute Kidney Injury; Adult; Anesthesia; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Respiratory Insufficiency; Substance Withdrawal Syndrome; Thyroid Hormones | 1999 |
A pilot study of naltrexone-accelerated detoxification in opioid dependence.
Topics: Adolescent; Adult; Analgesics; Anti-Anxiety Agents; Clonidine; Conscious Sedation; Female; Flunitrazepam; Heroin; Heroin Dependence; Hormones; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Octreotide; Pilot Projects; Substance Withdrawal Syndrome; Time Factors | 1999 |
Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.
Topics: Adult; Analgesics, Opioid; Constipation; Double-Blind Method; Female; Gastrointestinal Transit; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Statistics, Nonparametric; Substance Withdrawal Syndrome | 2000 |
Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Clonidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; GABA Agents; Heroin Dependence; Humans; Inactivation, Metabolic; Ketoprofen; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Oxazepam; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome | 2000 |
Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combination; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Substance Withdrawal Syndrome; Trazodone | 2000 |
Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification.
Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome | 2000 |
Oral methylnaltrexone for opioid-induced constipation.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Constipation; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Quaternary Ammonium Compounds; Single-Blind Method | 2000 |
24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures.
Topics: Administration, Oral; Adult; Aftercare; Anti-Anxiety Agents; Benzodiazepines; Clonidine; Drug Implants; Female; Follow-Up Studies; Heroin Dependence; Home Care Services, Hospital-Based; Humans; Male; Methadone; Naltrexone; Octreotide; Opioid-Related Disorders; Patient Admission; Substance Withdrawal Syndrome; Time Factors | 2002 |
Interaction between naltrexone and oral THC in heavy marijuana smokers.
Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Analysis of Variance; Choice Behavior; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Drug Interactions; Female; Heart Rate; Humans; Male; Marijuana Smoking; Methadone; Naltrexone; Narcotic Antagonists; Pain Measurement; Psychomotor Performance; Reaction Time | 2003 |
Use of very low-dose naltrexone during opiate detoxification.
Topics: Adult; Drug Administration Schedule; Female; Humans; Inactivation, Metabolic; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 2003 |
Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study.
Topics: Administration, Oral; Administration, Sublingual; Adolescent; Adult; Age Distribution; Buprenorphine; Humans; Male; Methadone; Middle Aged; Naltrexone; Socioeconomic Factors; Substance Abuse, Intravenous; Treatment Outcome | 2003 |
Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
Topics: Adult; Ambulatory Care; Biological Availability; Combined Modality Therapy; Comorbidity; Delayed-Action Preparations; Drug Administration Schedule; Drug Implants; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Mental Disorders; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Premedication; Psychotherapy; Spain; Treatment Outcome | 2003 |
Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD)--correlation with neurophysiological parameters--.
Topics: Acetates; Adult; Amines; Anesthesia; Anesthetics, Intravenous; Cyclohexanecarboxylic Acids; Electric Stimulation; Evoked Potentials, Somatosensory; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Heroin Dependence; Hormone Antagonists; Humans; Magnesium; Male; Median Nerve; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Potassium; Propofol; Restless Legs Syndrome; Somatostatin; Substance Withdrawal Syndrome; Water-Electrolyte Balance | 2004 |
A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
Topics: Administration, Oral; Adult; Affect; Delayed-Action Preparations; Drug Administration Schedule; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Outcome and Process Assessment, Health Care; Personality Inventory; Psychometrics; Secondary Prevention; Substance Withdrawal Syndrome | 2006 |
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Cocaine; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Heroin Dependence; Humans; Injections, Subcutaneous; Male; Methadone; Middle Aged; Naltrexone; Narcotics; Placebos; Secondary Prevention; Substance Abuse Detection; Treatment Outcome | 2006 |
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.
Topics: Adult; Depression; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists | 2006 |
Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.
Topics: Adult; Analgesics, Opioid; Community Mental Health Services; Disruptive, Impulse Control, and Conduct Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Inactivation, Metabolic; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Program Development; Substance Withdrawal Syndrome | 2009 |
Naltrexone implants compared to methadone: outcomes six months after prison release.
Topics: Adult; Crime; Drug Implants; Female; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Prisons; Secondary Prevention | 2010 |
Problem drinking and low-dose naltrexone-assisted opioid detoxification.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Severity of Illness Index; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2011 |
The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cross-Over Studies; Dietary Sucrose; Double-Blind Method; England; Female; Food Preferences; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Osmolar Concentration; Sodium Chloride, Dietary; Taste Perception; Taste Threshold; Young Adult | 2013 |
Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naive methadone-intoxicated patients.
Topics: Adolescent; Adult; Analgesics, Opioid; Double-Blind Method; Female; Humans; Iran; Male; Methadone; Naltrexone; Respiration Disorders; Young Adult | 2013 |
Extended-release naltrexone opioid treatment at jail reentry (XOR).
Topics: Analgesics, Opioid; Cause of Death; Delayed-Action Preparations; Drug Overdose; Humans; Injections, Intramuscular; Methadone; Mortality; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Participation; Prisons; Secondary Prevention | 2016 |
The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Topics: Analgesics, Opioid; Cooperative Behavior; Criminal Law; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; National Institute on Drug Abuse (U.S.); Opiate Substitution Treatment; Opioid-Related Disorders; Patient Navigation; Prisoners; Prisons; Treatment Outcome; United States | 2016 |
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
Topics: Adaptation, Psychological; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Combined Modality Therapy; Drug Users; Health Services Accessibility; Humans; Methadone; Mobile Applications; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life; Recurrence; Research Design; Smartphone; Telemedicine; Time Factors; Treatment Outcome; Wisconsin | 2016 |
Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Dog Diseases; Dogs; Fluconazole; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Topics: Adult; Animals; Benzazepines; Buprenorphine; Delayed-Action Preparations; Female; Humans; Injections; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome; Swine | 2021 |
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Hepatitis C; HIV Infections; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; RNA; Social Justice | 2022 |
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
286 other study(ies) available for methadone and naltrexone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Behavioral effects of narcotic analgesics administered alone or in combination with narcotic antagonists.
Topics: Analgesics, Opioid; Animals; Avoidance Learning; Behavior, Animal; Drug Interactions; Electroshock; Haplorhini; Macaca fascicularis; Methadone; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Time Factors | 1976 |
Letter: Treatment of accidental naltrexone-induced withdrawal.
Topics: Adult; Humans; Hydromorphone; Male; Methadone; Naloxone; Naltrexone; Substance Withdrawal Syndrome | 1976 |
Conditioned drug responses to naturalistic stimuli.
Topics: Conditioning, Psychological; Heart Rate; Humans; Hydromorphone; Methadone; Naltrexone; Opioid-Related Disorders; Personality Tests; Self Administration; Skin Temperature | 1979 |
Aversiveness of oral methadone in rats.
Topics: Animals; Choice Behavior; Decision Making; Heroin Dependence; Humans; Male; Methadone; Models, Psychological; Naltrexone; Quinine; Rats; Self Administration; Taste; Time Factors | 1978 |
Naltrexone: the clinical investigator's dilemma.
Topics: Adolescent; Adult; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Patient Dropouts; Research Design; Social Adjustment; United States | 1978 |
Clonidine hydrochloride: a nonopiate treatment for opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1979 |
The clinical usefulness of narcotic antagonists: implications of behavioral research.
Topics: Aftercare; Behavior Therapy; Conditioning, Operant; Cyclazocine; Extinction, Psychological; Heroin; Heroin Dependence; Hospitalization; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Patient Dropouts; Reinforcement, Psychology; Research Design; Self-Assessment | 1975 |
Opioid peptides and opiates differ in receptor selectivity.
Topics: Animals; Brain; Dextrorphan; Endorphins; Enkephalins; Isomerism; Levorphanol; Methadone; Morphine; Naloxone; Naltrexone; Rats; Receptors, Opioid | 1977 |
Methadone maintenance and narcotic blocking drugs.
Topics: Aftercare; Cyclazocine; Extinction, Psychological; Heroin Dependence; Hospitalization; Humans; Levallorphan; Methadone; Nalorphine; Naloxone; Naltrexone; Narcotic Antagonists; Psychotherapy; Receptors, Opioid | 1977 |
Update of naltrexone treatment.
Topics: Adult; Conditioning, Psychological; Female; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotics; Receptors, Opioid; Social Adjustment; Substance Withdrawal Syndrome; Substance-Related Disorders | 1978 |
Naltrexone in the treatment of opiate dependence.
Topics: Adolescent; Adult; Follow-Up Studies; Forecasting; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotics; New York City; Psychotherapy; Receptors, Opioid; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders | 1978 |
Inhibition by d,l-methadone of RNA and protein synthesis in neonatal mice: antagonism by naloxone or naltrexone.
Topics: Animals; Animals, Newborn; Depression, Chemical; Liver; Methadone; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Protein Biosynthesis; RNA; Time Factors | 1978 |
Midbrain raphe mediation of the narcotic blockade of ovulation.
Topics: Animals; Brain Stem; Female; Luteinizing Hormone; Mesencephalon; Methadone; Morphine; Naltrexone; Ovulation; Raphe Nuclei; Rats | 1978 |
Evaluation of narcotic and narcotic antagonist interactions in primates.
Topics: Animals; Cyclazocine; Dextroamphetamine; Diazepam; Drug Interactions; Ethanol; Female; Haplorhini; Humans; Macaca mulatta; Male; Methadone; Methadyl Acetate; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Phenytoin; Secobarbital; Self Administration | 1976 |
Naloxone-precipitated withdrawal: a method for rapid induction onto naltrexone.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Heroin Dependence; Humans; Male; Methadone; Methods; Naloxone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders | 1977 |
Naltrexone treatment of opiate-dependent persons.
Topics: Adult; Humans; Male; Methadone; Middle Aged; Naloxone; Naltrexone; Narcotics; Substance-Related Disorders | 1977 |
Pharmacotherapy of opiate addiction.
Topics: Adolescent; Adult; Cyclazocine; Female; Heroin Dependence; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Opium; Substance-Related Disorders; United States | 1976 |
Inhibition of nucleic acid synthesis in the regenerating limb of salamanders treated with a DL-methadone or narcotic antagonists.
Topics: Animals; Cyclazocine; Depression, Chemical; DNA; Extremities; Methadone; Naltrexone; Narcotic Antagonists; Regeneration; RNA; Urodela | 1976 |
Long-acting narcotic antagonist complexes.
Topics: Animals; Brain; Diprenorphine; Methadone; Mice; Morphine; Naltrexone; Narcotic Antagonists; Reaction Time; Time Factors | 1976 |
Psychopathology and mood during heroin use: acute vs chronic effects.
Topics: Acute Disease; Adult; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emotions; Euphoria; Heroin; Heroin Dependence; Humans; Male; Methadone; Morphine; Motor Activity; Naloxone; Naltrexone; Psychopathology | 1976 |
An analysis of naltrexone use--its efficacy, safety and potential.
Topics: Adult; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Methadone; Middle Aged; MMPI; Naloxone; Naltrexone; Outpatient Clinics, Hospital; Patient Compliance; Patient Dropouts; Personality Inventory; Substance-Related Disorders | 1976 |
Interactions of narcotics, narcotic antagonists, and ethanol during acute, chronic, and withdrawal states.
Topics: Alcohol Drinking; Animals; Animals, Newborn; Dextrorphan; Drug Interactions; Ethanol; Humans; Levorphanol; Male; Methadone; Methadyl Acetate; Mice; Mice, Inbred C57BL; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rats; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1976 |
A unit for delivering multiple drug treatment and prevention services.
Topics: Adolescent; Adult; Community Mental Health Services; Connecticut; Cyclazocine; Heroin Dependence; Humans; Methadone; Naltrexone; Psychotherapy, Group; Substance-Related Disorders; Vocational Education | 1975 |
On the role of chemotherapy in the treatment of heroin addiction.
Topics: Heroin Dependence; Humans; Methadone; Methadyl Acetate; Motivation; Naloxone; Naltrexone; Substance-Related Disorders | 1975 |
Clinical experience with naltrexone.
Topics: Administration, Oral; Adult; Female; Heroin Dependence; Hospitalization; Humans; Male; Methadone; Middle Aged; Morphine; Naloxone; Naltrexone; Outpatient Clinics, Hospital; Patient Dropouts; Placebos; Time Factors | 1975 |
Patient deaths in a narcotic antagonist (naltrexone) and l-alpha-acetylmethadol program.
Topics: Adult; Heroin Dependence; Homicide; Humans; Male; Methadone; Methadyl Acetate; Naloxone; Naltrexone; Psychotropic Drugs; Substance-Related Disorders; Suicide | 1975 |
Long-acting narcotic antagonist complexes.
Topics: Aluminum; Animals; Brain; Buffers; Chemistry, Pharmaceutical; Delayed-Action Preparations; Diprenorphine; Drug Stability; Methadone; Mice; Morphine; Naltrexone; Narcotic Antagonists; Reaction Time; Zinc | 1975 |
Heroin addiction. Sequential treatment employing pharmacologic supports.
Topics: Heroin Dependence; Humans; Methadone; Morphine; Naltrexone; Prognosis; Recurrence | 1976 |
Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Behavior, Animal; Benzodiazepines; Benzomorphans; Drug Interactions; Ethylketocyclazocine; Male; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Nociceptors; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Saimiri; Urination | 1992 |
Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells.
Topics: Binding Sites; Calcium; Cell Death; Cell Division; Cell Membrane; Cyclic AMP; Cycloheximide; Dactinomycin; Growth Inhibitors; Humans; Methadone; Morphine; Naltrexone; Nicotine; Pertussis Toxin; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Stereoisomerism; Tumor Cells, Cultured; Virulence Factors, Bordetella | 1992 |
Effect of adrenal and sex hormones on opioid analgesia and opioid receptor regulation.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Analgesics; Animals; Brain; Female; Gonadal Steroid Hormones; Male; Methadone; Mice; Morphine; Naltrexone; Narcotics; Orchiectomy; Ovariectomy; Reaction Time; Receptors, Opioid; Sex Characteristics; Up-Regulation | 1992 |
Opioidergic modulation of cocaine conditioned place preferences.
Topics: Analysis of Variance; Animals; Cocaine; Conditioning, Psychological; Male; Methadone; Naltrexone; Rats; Rats, Inbred Strains; Reference Values; Reinforcement, Psychology | 1992 |
The partial opioid agonist, buprenorphine, protects against lethal effects of cocaine.
Topics: Animals; Brain; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Methadone; Mice; Mice, Inbred Strains; Morphine; Naltrexone; Receptors, Opioid; Receptors, Opioid, mu; Seizures | 1991 |
Rapid transition from methadone maintenance to naltrexone.
Topics: Flumazenil; Humans; Methadone; Midazolam; Naltrexone; Substance Withdrawal Syndrome | 1990 |
Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methadone; Midazolam; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1991 |
Opioid agonist affinity in the guinea-pig ileum and mouse vas deferens.
Topics: Animals; Cyclazocine; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Enkephalins; Ethylketocyclazocine; Guinea Pigs; Ileum; Male; Methadone; Mice; Morphine; Morphine Derivatives; Naltrexone; Receptors, Opioid; Vas Deferens | 1990 |
Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Butorphanol; Dose-Response Relationship, Drug; Levallorphan; Male; Methadone; Morphinans; Nalbuphine; Nalorphine; Naltrexone; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Saimiri | 1990 |
Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
Topics: Analgesics; Animals; Dose-Response Relationship, Drug; Fentanyl; Levorphanol; Male; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, mu; Time Factors | 1990 |
Evidence of single dose opioid dependence in 12- to 14-day-old chicken embryos.
Topics: 1-Methyl-3-isobutylxanthine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Chick Embryo; Methadone; Morphine Dependence; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pyrrolidines; Receptors, Opioid; Substance Withdrawal Syndrome | 1989 |
From theory to practice: the planned treatment of drug users. Interview by Stanley Einstein.
Topics: Aftercare; Combined Modality Therapy; Humans; Methadone; Motivation; Naltrexone; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Therapeutic Community | 1989 |
NIDA's Medication Development Program--1989.
Topics: Acquired Immunodeficiency Syndrome; Brain; Cocaine; Drug and Narcotic Control; Female; Heroin Dependence; Humans; Infant, Newborn; Methadone; Methadyl Acetate; Naltrexone; Pregnancy; Psychotropic Drugs; Research Support as Topic; Risk Factors; Substance Abuse, Intravenous; Substance-Related Disorders | 1989 |
Naltrexone treatment--the problem of patient acceptance.
Topics: Adult; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Patient Acceptance of Health Care | 1989 |
Endogenous opioids in cerebrospinal fluid of opioid-dependent humans.
Topics: Adult; beta-Endorphin; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Radioimmunoassay; Radioligand Assay; Receptors, Opioid; Substance Withdrawal Syndrome | 1988 |
Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.
Topics: Animals; Benzomorphans; Caudate Nucleus; Dopamine; Male; Methadone; Morphine; Motor Activity; Naloxone; Naltrexone; Nucleus Accumbens; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Reward; Septal Nuclei | 1988 |
Analeptic effect of opiate receptor agonists in rabbits.
Topics: Animals; Arousal; Brain; Central Nervous System Stimulants; Codeine; Cyclazocine; Dose-Response Relationship, Drug; Enkephalin, Methionine; Ethylketocyclazocine; Etorphine; Male; Meperidine; Methadone; Morphine; Naltrexone; Narcotics; Phenazocine; Rabbits; Receptors, Opioid; Reflex | 1985 |
The role of drugs in the treatment of opioid addicts.
Topics: Alcoholism; Anxiety; Clonidine; Dextropropoxyphene; Heroin; Humans; Inactivation, Metabolic; Kinetics; Methadone; Mood Disorders; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1986 |
Role of opioid antagonists in treating intravenous cocaine abuse.
Topics: Adult; Buprenorphine; Cocaine; Female; Humans; Injections, Intravenous; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance-Related Disorders | 1989 |
High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications.
Topics: Anesthesia, Spinal; Animals; Blood Pressure; Cats; Drug Tolerance; Fentanyl; Hyperesthesia; Methadone; Morphine; Morphine Derivatives; Naltrexone; Rats; Receptors, Drug; Stimulation, Chemical; Strychnine; Sufentanil; Sulfates; Touch | 1986 |
Opiate addiction and plasma beta-endorphin-like immunoreactivity: methadone maintained, recently detoxified and early naltrexone treated ex-addicts.
Topics: Adult; beta-Endorphin; Endorphins; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Time Factors | 1987 |
Naltrexone.
Topics: Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain; Pituitary Gland; Receptors, Opioid; Substance Withdrawal Syndrome | 1985 |
Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesia; Animals; Biological Assay; Buprenorphine; Butorphanol; Cyclazocine; Dose-Response Relationship, Drug; Ethylketocyclazocine; Etorphine; Fentanyl; Methadone; Mice; Morphine; Muscle Contraction; Nalbuphine; Nalorphine; Naltrexone; Pyrrolidines; Receptors, Opioid; Receptors, Opioid, mu | 1987 |
CSF endorphins in chronic opioid-dependent humans.
Topics: Endorphins; Humans; Male; Methadone; Naltrexone; Narcotics; Substance-Related Disorders | 1986 |
Naltrexone: lack of effect on hepatic enzymes.
Topics: Adult; Aspartate Aminotransferases; Heroin Dependence; Humans; L-Lactate Dehydrogenase; Liver; Liver Function Tests; Male; Methadone; Naltrexone; Substance-Related Disorders; Time Factors | 1988 |
Primary care of parenteral substance abusers.
Topics: Acquired Immunodeficiency Syndrome; Administration, Intranasal; Antibodies, Viral; Body Weight; Cocaine; Female; Heart Diseases; Hepatitis; Heroin Dependence; HIV Antibodies; Humans; Injections, Intradermal; Injections, Intravenous; Kidney Diseases; Male; Menstruation Disturbances; Methadone; Naltrexone; Nervous System Diseases; Primary Health Care; Respiratory Tract Diseases; Substance-Related Disorders | 1986 |
The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study.
Topics: Adult; Combined Modality Therapy; Female; Follow-Up Studies; Hospitals, University; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Psychiatric Department, Hospital; Recurrence; Social Adjustment | 1987 |
The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone.
Topics: Adult; Blood Pressure; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Methadone; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders | 1986 |
Psychosocial adjustment, modality choice, and outcome in naltrexone versus methadone treatment.
Topics: Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Social Adjustment | 1986 |
Psychosocial factors in outcome in two opiate addiction treatments.
Topics: Adult; Family; Female; Humans; Life Change Events; Male; Methadone; Middle Aged; Motivation; Naltrexone; Opioid-Related Disorders; Patient Compliance; Psychophysiologic Disorders; Social Support; Somatoform Disorders | 1986 |
Effects of opioids and phencyclidine in combination with naltrexone on the acquisition and performance of response sequences in monkeys.
Topics: Animals; Cyclazocine; Dose-Response Relationship, Drug; Erythrocebus patas; Female; Heroin; Methadone; Naloxone; Naltrexone; Narcotics; Phencyclidine; Reinforcement Schedule; Serial Learning | 1985 |
Clonidine hydrochloride detoxification from methadone treatment--the value of naltrexone aftercare.
Topics: Adult; Aftercare; Attitude to Health; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1984 |
Anti-endorphin effects of methadone.
Topics: Endorphins; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1980 |
Clonidine and opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1980 |
The effects of opiate agonists on growth hormone and prolactin release in rats.
Topics: Animals; Apomorphine; Enkephalins; Growth Hormone; Male; Methadone; Morphine; Naloxone; Naltrexone; Parasympathomimetics; Prolactin; Rats; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Opioid; Secretory Rate | 1980 |
Methadone-induced endorphin dysfunction in addicts.
Topics: Adrenocorticotropic Hormone; Brain; Endorphins; Humans; Hydrocortisone; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid; Substance Withdrawal Syndrome | 1982 |
Effect of chronic naltrexone and methadone administration on brain immunoreactive beta-endorphin in the rat.
Topics: Animals; beta-Endorphin; Brain Chemistry; Endorphins; Hypothalamus; Male; Methadone; Naloxone; Naltrexone; Radioimmunoassay; Rats; Rats, Inbred Strains | 1983 |
Nonspecific convulsions are induced by morphine but not D-Ala2-methionine-enkephalinamide at cortical sites.
Topics: Animals; Cerebral Cortex; Drug Tolerance; Electroencephalography; Enkephalin, Methionine; Evoked Potentials; Injections, Intraventricular; Male; Methadone; Morphine; Naltrexone; Rats; Rats, Inbred Strains; Receptors, Opioid; Seizures | 1984 |
Use of naltrexone to extinguish opioid-conditioned responses.
Topics: Adult; Combined Modality Therapy; Conditioning, Classical; Extinction, Psychological; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Recurrence; Relaxation Therapy | 1984 |
Recent advances in opiate detoxification: clonidine and lofexidine.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
The index of choice: indications of methadone patients' selection of naltrexone treatment.
Topics: Adult; Attitude; Humans; Internal-External Control; Male; Methadone; Motivation; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Acceptance of Health Care; Prospective Studies; Self Concept; Social Environment | 1984 |
Strategies to improve compliance with narcotic antagonists.
Topics: Combined Modality Therapy; Humans; Life Style; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Patient Dropouts; Research; Social Support; Substance Withdrawal Syndrome | 1984 |
Methadone and naltrexone in the treatment of heroin dependence.
Topics: Heroin Dependence; Humans; Methadone; Naloxone; Naltrexone; Psychotherapy; Substance Withdrawal Syndrome; Time Factors | 1984 |
Latent inhibition in the aversion to oral methadone.
Topics: Animals; Avoidance Learning; Extinction, Psychological; Female; Male; Methadone; Naltrexone; Quinine; Rats; Rats, Inbred Strains; Time Factors | 1984 |
Clonidine hydrochloride detoxification from methadone treatments: the value of naltrexone aftercare.
Topics: Adolescent; Clonidine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Opium; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 1981 |
Effects of selected opioid agonists and antagonists on DMT- and LSD-25-induced disruption of food-rewarded bar pressing behavior in the rat.
Topics: Animals; Conditioning, Operant; Drug Interactions; Drug Synergism; Lysergic Acid Diethylamide; Male; Methadone; Morphine; N,N-Dimethyltryptamine; Naloxone; Naltrexone; Narcotics; Rats; Reinforcement, Psychology; Tryptamines | 1981 |
Endorphin levels in opioid-dependent human subjects: a longitudinal study.
Topics: Adult; Endorphins; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome.
Topics: Adult; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Therapeutic Community | 1982 |
Outpatient opiate detoxification with clonidine.
Topics: Ambulatory Care; Clonidine; Double-Blind Method; Drug Therapy, Combination; Heroin Dependence; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
Cardiac and autonomic nervous system effects of L-alphacetylmethadol (LAAM).
Topics: Animals; Atropine; Autonomic Nervous System; Blood Pressure; Calcium; Drug Interactions; Electric Stimulation; Guinea Pigs; Heart; In Vitro Techniques; Male; Methadone; Methadyl Acetate; Naltrexone; Norepinephrine | 1982 |
Blockade of ovulation by methadone in the rat: a central nervous system-mediated acute effect.
Topics: Animals; Central Nervous System; Electric Stimulation; Female; Luteinizing Hormone; Male; Methadone; Naltrexone; Ovulation; Preoptic Area; Rats | 1980 |
Methadone reduces sexual performances and sexual motivation in the male Syrian golden hamster.
Topics: Animals; Cricetinae; Dose-Response Relationship, Drug; Male; Mesocricetus; Methadone; Naltrexone; Sexual Behavior, Animal | 1981 |
Clinical pharmacology of mixed agonist-antagonist drugs [proceedings].
Topics: Buprenorphine; Cyclazocine; Humans; Methadone; Morphinans; Morphine Dependence; Naltrexone | 1981 |
The clinical use of clonidine in outpatient detoxification from opiates.
Topics: Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Self Administration; Substance Withdrawal Syndrome | 1981 |
[Role of LAAM, methadone and naltrexone in the care of opiate dependence. Experience in Portugal].
Topics: Drug Administration Schedule; Female; Heroin Dependence; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Narcotics; Patient Compliance; Portugal; Substance-Related Disorders; Time Factors | 1994 |
Role of increase of opioid receptors in granulocyte CD11b/CD18 dysfunction.
Topics: Adult; Antigens, CD; CD18 Antigens; Female; Granulocytes; Heroin Dependence; Humans; Macrophage-1 Antigen; Male; Methadone; Naltrexone; Phagocytosis; Receptors, Opioid | 1993 |
A novel delta opioid agonist, BW373U86, in squirrel monkeys responding under a schedule of shock titration.
Topics: Amino Acid Sequence; Animals; Behavior, Animal; Benzamides; Drug Interactions; Drug Tolerance; Electroshock; Male; Methadone; Molecular Sequence Data; Naltrexone; Narcotic Antagonists; Nociceptors; Piperazines; Receptors, Opioid, delta; Receptors, Opioid, mu; Saimiri | 1993 |
Can psychotherapy rescue naltrexone treatment of opioid addiction?
Topics: Combined Modality Therapy; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Psychotherapy | 1995 |
Effects of chronic treatment with methadone and naltrexone on sleep in addicts.
Topics: Adult; Analgesics, Opioid; Female; Heroin; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Sleep; Substance-Related Disorders | 1996 |
The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 1996 |
Methadone vs naltrexone.
Topics: Connecticut; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 1997 |
Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys.
Topics: Animals; Buprenorphine; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Methadone; Methadyl Acetate; Morphine; Naltrexone; Narcotic Antagonists; Narcotics | 1997 |
Neonatal withdrawal following pre- and postnatal exposure to methadone in the rat.
Topics: Animals; Animals, Newborn; Behavior, Animal; Female; Humans; Infant, Newborn; Male; Methadone; Motor Activity; Naltrexone; Narcotic Antagonists; Neonatal Abstinence Syndrome; Pregnancy; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Vocalization, Animal | 1998 |
Apparent thermodynamic parameters of ligand binding to the cloned rat mu-opioid receptor.
Topics: Analgesics; Animals; Binding, Competitive; CHO Cells; Cricetinae; Diprenorphine; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Fentanyl; Ligands; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Pentazocine; Peptide Fragments; Peptides; Radioligand Assay; Rats; Receptors, Opioid, mu; Somatostatin; Sufentanil; Thermodynamics; Time Factors | 1998 |
Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage.
Topics: Adult; Dose-Response Relationship, Drug; Female; Heroin Dependence; Humans; Italy; Male; Methadone; Naltrexone; Patient Dropouts | 1998 |
Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results.
Topics: Administration, Oral; Adolescent; Adult; Anesthesia, General; Clonidine; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Heroin Dependence; Humans; Hypnotics and Sedatives; Length of Stay; Male; Methadone; Midazolam; Naltrexone; Narcotic Antagonists; Neurologic Examination; Ondansetron; Substance Withdrawal Syndrome; Treatment Outcome | 1998 |
The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.
Topics: Animals; Buprenorphine; Butorphanol; Columbidae; Discrimination Learning; Female; Fentanyl; Levallorphan; Methadone; Morphine; Nalbuphine; Nalorphine; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 1998 |
Maintenance programmes are denied to addicted prisoners in Victoria.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Prisoners; Victoria | 1999 |
Is naltrexone a cure for heroin dependence?
Topics: Australia; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Pilot Projects; Substance Withdrawal Syndrome | 1999 |
Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone.
Topics: Adult; Anesthetics, Intravenous; Emergencies; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Propofol; Substance Withdrawal Syndrome | 1999 |
Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study.
Topics: Adult; Analgesics, Opioid; Constipation; Female; Gastrointestinal Motility; Gastrointestinal Transit; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Quaternary Ammonium Compounds | 1999 |
Serendipitous rapid detoxification from opiates: the importance of time-dependent processes.
Topics: Adult; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome; Time Factors | 1999 |
Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Dextroamphetamine; Dose-Response Relationship, Drug; Fentanyl; Male; Methadone; Morphine; Nalbuphine; Nalorphine; Naltrexone; Narcotic Antagonists; Narcotics; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2000 |
Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts.
Topics: Adult; Anesthesia, General; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; Morphine Dependence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prospective Studies; Substance Withdrawal Syndrome | 2000 |
Managing constipation that's opioid-induced.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Breast Neoplasms; Chemistry, Pharmaceutical; Constipation; Female; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Pain; Quaternary Ammonium Compounds | 2000 |
Morphine discriminative control is mediated by the mu opioid receptor: assessment of delta opioid substitution and antagonism.
Topics: Animals; Benzamides; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Female; Generalization, Response; Methadone; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Piperazines; Rats; Rats, Long-Evans; Receptors, Opioid, delta; Receptors, Opioid, mu | 2000 |
Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts.
Topics: Adult; Aged; Brain; Female; Fluorine Radioisotopes; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Naltrexone; Receptors, Opioid, kappa; Receptors, Opioid, mu; Tomography, Emission-Computed | 2000 |
[Evolution and update of detoxification techniques for opiate addicts].
Topics: Animals; Buprenorphine; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2000 |
Methadone enhances human immunodeficiency virus infection of human immune cells.
Topics: Adult; Drug Interactions; Fetus; HIV Infections; Humans; Immunosuppressive Agents; Macrophages; Methadone; Microglia; Middle Aged; Monocytes; Morphine; Naltrexone; Narcotics; Receptors, CCR5 | 2002 |
Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon.
Topics: Buprenorphine; Electrocardiography; Heroin Dependence; Humans; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Time Factors | 2001 |
[Surprising conclusion by the SBU concerning the benefits of naltrexone in the treatment of heroin dependence].
Topics: Controlled Clinical Trials as Topic; Evidence-Based Medicine; Heroin Dependence; Humans; Meta-Analysis as Topic; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
[Documented effect of methadone, but not naltrexone].
Topics: Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Treatment Outcome | 2002 |
[Methadone and naltrexone in heroin addiction--an explanation from the SBU].
Topics: Evidence-Based Medicine; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Social Support; Sweden | 2002 |
Conservative management with naltrexone of an iatrogenic methadone overdose in an opiate-naive patient.
Topics: Alcoholism; Cocaine-Related Disorders; Diagnosis, Dual (Psychiatry); Drug Overdose; Humans; Male; Medication Errors; Methadone; Middle Aged; Naltrexone; Schizophrenia | 2002 |
Methylnaltrexone reverses opioid-induced constipation.
Topics: Administration, Oral; Analgesics, Opioid; Clinical Trials, Phase II as Topic; Constipation; Humans; Methadone; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds | 2002 |
Dangers involved in rapid opioid detoxification while using opioid antagonists: dehydration and renal failure.
Topics: Acute Kidney Injury; Adult; Dehydration; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 2002 |
Behavioral naltrexone therapy: an integrated treatment for opiate dependence.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Compliance; Time Factors; Treatment Outcome | 2002 |
Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
Topics: Acute Disease; Analgesics, Opioid; Animals; Disease Models, Animal; Fentanyl; Male; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders | 2003 |
Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Electric Conductivity; Endocytosis; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; GTP-Binding Proteins; Methadone; Mice; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Neuroblastoma; Pentazocine; Pituitary Neoplasms; Receptors, Opioid, mu; Transfection; Tumor Cells, Cultured | 2003 |
Experiences with an outpatient relapse program (community reinforcement approach) combined with naltrexone in the treatment of opioid-dependence: effect on addictive behaviors and the predictive value of psychiatric comorbidity.
Topics: Adult; Combined Modality Therapy; Community Mental Health Services; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Mental Disorders; Methadone; Naltrexone; Narcotic Antagonists; Patient Care Team; Patient Compliance; Patient Dropouts; Psychotherapy; Reinforcement, Psychology; Secondary Prevention | 2003 |
Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
Topics: Animals; Cinnamates; Columbidae; Female; Fentanyl; Methadone; Morphine; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Narcotics; Reaction Time; Receptors, Opioid, mu; Sufentanil | 2003 |
Clinical treatment of opioid addiction and dependence.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Humans; Inactivation, Metabolic; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2003 |
Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone.
Topics: Administration, Oral; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Interactions; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Pain | 2003 |
[Detoxification in withdrawal state in methadone maintenance patients].
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Data Interpretation, Statistical; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome | 2003 |
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2004 |
Unexpected delirium during Rapid Opioid Detoxification (ROD).
Topics: Adult; Alcohol Withdrawal Delirium; Clonidine; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Inactivation, Metabolic; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2004 |
Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user.
Topics: Australia; Drug Implants; Female; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2004 |
Orthoptic status before and immediately after heroin detoxification.
Topics: Accommodation, Ocular; Adolescent; Adult; Convergence, Ocular; Diplopia; Eye Movements; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotics; Refractive Errors; Vision, Binocular; Visual Acuity | 2004 |
Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project.
Topics: Adolescent; Adult; Ambulatory Care; Analgesics, Opioid; Anesthesia; Buprenorphine; Female; Heroin Dependence; Hospitalization; Humans; Hypnotics and Sedatives; Inactivation, Metabolic; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2005 |
A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Chi-Square Distribution; Cost-Benefit Analysis; Female; Heroin Dependence; Humans; Hypnotics and Sedatives; Male; Methadone; Naltrexone; Narcotic Antagonists | 2006 |
Effect of repeated administrations of heroin, naltrexone, methadone, and alcohol on morphine glucuronidation in the rat.
Topics: Animals; Ethanol; Heroin; Heroin Dependence; Male; Methadone; Microsomes, Liver; Morphine; Morphine Derivatives; Naltrexone; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu | 2005 |
Medicalising the treatment of opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 2006 |
Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.
Topics: Adult; Blood Pressure; Cannabinoids; Dronabinol; Female; Hallucinogens; Heart Rate; Humans; Male; Marijuana Smoking; Mental Recall; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Psychomotor Performance; Pupil; Recognition, Psychology; Sex Characteristics; Surveys and Questionnaires | 2007 |
Naltrexone-assisted rapid methadone discontinuation: a pilot study.
Topics: Adult; Drug Evaluation, Preclinical; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Pilot Projects; Substance Withdrawal Syndrome; Treatment Outcome | 2007 |
Regarding naltrexone for probationers and parolees.
Topics: Buprenorphine; Heroin Dependence; Humans; Injections; Long-Term Care; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Pain; Prisoners; Treatment Outcome | 2007 |
Medical treatment of opiate dependence: expanding treatment options.
Topics: Administration, Sublingual; Ambulatory Care; Buprenorphine; Drug Combinations; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Randomized Controlled Trials as Topic; Substance Abuse Detection; Treatment Outcome | 2007 |
Does naltrexone affect craving in abstinent opioid-dependent patients?
Topics: Adult; Female; Heroin; Heroin Dependence; Humans; Longitudinal Studies; Male; Methadone; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2007 |
Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
Topics: Australia; Buprenorphine; Drug Prescriptions; Drug Therapy; Episode of Care; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries | 2007 |
Hepatitis C treatment, subcutaneous naltrexone implants, and methadone maintenance treatment.
Topics: Antiviral Agents; Drug Implants; Hepatitis C; Humans; Methadone; Morphine Dependence; Naltrexone; Narcotics | 2007 |
Pharmacotherapeutic environments for substance use disorders.
Topics: Ambulatory Care; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Family Practice; Heroin Dependence; Hospitalization; Humans; Methadone; Naltrexone; Office Visits; Opioid-Related Disorders; Secondary Prevention; Substance-Related Disorders | 2007 |
Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
Topics: Adult; Cohort Studies; Databases, Factual; Drug Implants; Drug Overdose; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Suicide; Time Factors; Western Australia | 2008 |
Behavioral economic analysis of drug preference using multiple choice procedure data.
Topics: Choice Behavior; Economics; Fentanyl; Fluoxetine; Hallucinogens; Humans; Hydromorphone; Injections, Intramuscular; Methadone; Models, Psychological; Motivation; N-Methyl-3,4-methylenedioxyamphetamine; Naltrexone; Narcotics; Psychotropic Drugs; Recreation; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous; Substance-Related Disorders | 2008 |
Toward a rational selection of treatment for addiction.
Topics: Alleles; Buprenorphine; Genetic Variation; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu; Substance-Related Disorders | 2007 |
Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
Topics: Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Implants; Female; Follow-Up Studies; Heroin Dependence; Hospitalization; Humans; Male; Methadone; Morbidity; Naltrexone; Narcotics; Prevalence; Prospective Studies; Retrospective Studies | 2008 |
Community treatment programs take up buprenorphine.
Topics: Buprenorphine; Humans; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Selection; Substance Abuse Treatment Centers | 2004 |
A 50-year-old woman addicted to heroin: review of treatment of heroin addiction.
Topics: Buprenorphine; Drug Therapy, Combination; Female; Heroin Dependence; History, 19th Century; History, 20th Century; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Recurrence; Self-Help Groups; United States | 2008 |
Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice.
Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Hypoglycemic Agents; Immunosuppressive Agents; Injections, Intraperitoneal; Insulin; Methadone; Mice; Naltrexone; Narcotic Antagonists; Pancreas; Receptors, Opioid, mu; Streptozocin; Time Factors | 2008 |
Substitution treatment in Malaysia.
Topics: Buprenorphine; Drug Utilization; Heroin Dependence; Humans; Malaysia; Methadone; Naltrexone; Patient Compliance; Pilot Projects; Policy Making | 2008 |
Insufficient information in drug-related hospital morbidity study.
Topics: Hospitals; Humans; Information Dissemination; Medication Errors; Methadone; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2009 |
Route of administration influences substitution patterns in rats trained to discriminate methadone vs. vehicle.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Non-Narcotic; Animals; Choice Behavior; Conditioning, Operant; Discrimination, Psychological; Heroin; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Methadone; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Pharmaceutical Vehicles; Rats; Rats, Sprague-Dawley; Stereoisomerism | 2009 |
Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats.
Topics: Animals; Blood Gas Analysis; Buprenorphine; Catheterization; Fentanyl; Lactic Acid; Male; Methadone; Morphine; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Narcotics; Plethysmography, Whole Body; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Respiratory Insufficiency; Respiratory Mechanics | 2009 |
Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Male; Methadone; Morphine; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Time Factors | 2009 |
First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction.
Topics: Adult; Drug Interactions; Echocardiography; Electrocardiography; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Substance Withdrawal Syndrome; Takotsubo Cardiomyopathy | 2010 |
Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance.
Topics: Adult; Australia; Diagnosis, Dual (Psychiatry); Drug Implants; Female; Heroin Dependence; Hospitalization; Humans; Longitudinal Studies; Male; Mental Disorders; Methadone; Naltrexone; Opiate Substitution Treatment; Prevalence | 2011 |
The diverse clinical uses of opioid receptor drugs.
Topics: Analgesics, Opioid; Buprenorphine; Drug Combinations; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists | 2010 |
Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the VEdeTTE study.
Topics: Adolescent; Adult; Aged; Female; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Psychotherapy; Social Support; Substance Abuse Treatment Centers; Treatment Outcome | 2010 |
Russian injected drug use soars in face of political inertia.
Topics: Drug Implants; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Politics; Russia; Substance Abuse, Intravenous | 2010 |
Addiction treatment in Russia.
Topics: Behavior, Addictive; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Russia; Substance Abuse, Intravenous; Suicide Prevention | 2010 |
Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
Topics: Animals; Calcium; Endocytosis; HEK293 Cells; Humans; Ligands; Methadone; Mice; Naltrexone; Protein Transport; Receptors, Opioid, delta; Receptors, Opioid, mu; Signal Transduction | 2011 |
THC-methadone and THC-naltrexone interactions on discrimination, antinociception, and locomotion in rats.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Discrimination Learning; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Locomotion; Male; Methadone; Naltrexone; Narcotic Antagonists; Pain; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu | 2011 |
Characterization of the antinociceptive effects of the individual isomers of methadone after acute and chronic administrations.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Male; Methadone; Naltrexone; Narcotic Antagonists; Pain; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, mu; Stereoisomerism | 2011 |
Promise of extended-release naltrexone is a red herring.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Russia | 2011 |
Injectable extended-release naltrexone for opioid dependence.
Topics: Administration, Oral; Delayed-Action Preparations; Drug Implants; Humans; Injections; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Russia | 2011 |
Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
Topics: Adult; Buprenorphine; Crime; Criminal Law; Data Collection; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pregnancy; Pregnancy Complications; Prisons; Substance-Related Disorders; Young Adult | 2012 |
[Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification].
Topics: Adult; Depression; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Young Adult | 2012 |
Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.
Topics: Analgesics; Analgesics, Opioid; Animals; Calcium Signaling; Data Interpretation, Statistical; Female; Fentanyl; HEK293 Cells; Humans; Injections, Spinal; Macaca mulatta; Male; Methadone; Mice; Naltrexone; Narcotic Antagonists; Pain Measurement; Receptors, Opioid, delta; Receptors, Opioid, mu | 2012 |
Opioid dependence.
Topics: Buprenorphine; Clonidine; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prognosis; Risk Factors; Substance Withdrawal Syndrome; Time Factors | 2012 |
Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Risk Assessment; Treatment Outcome | 2013 |
Blocking endogenous opioids during development--do we understand the consequences?
Topics: Animals; Brain; Buprenorphine; Female; Fetal Development; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Treatment Outcome | 2013 |
Impact of opioid pharmacotherapy on arterial stiffness and vascular ageing: cross-sectional and longitudinal studies.
Topics: Adult; Aging; Blood Vessels; Buprenorphine; Cross-Sectional Studies; Endothelium, Vascular; Female; Heroin Dependence; Humans; Longitudinal Studies; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Phenotype; Pulse Wave Analysis; Regression Analysis; Vascular Stiffness | 2013 |
Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signaling-insensitive Gαo protein.
Topics: Analgesics, Opioid; Animals; Brain; Diprenorphine; Dose-Response Relationship, Drug; Electric Stimulation; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Excitatory Amino Acid Antagonists; Female; GABA Antagonists; gamma-Aminobutyric Acid; Gene Expression Regulation; GTP-Binding Protein alpha Subunits, Gi-Go; Guanosine 5'-O-(3-Thiotriphosphate); Hot Temperature; Humans; Hyperalgesia; Inhibitory Postsynaptic Potentials; Isotopes; Male; Methadone; Mice; Mice, Transgenic; Morphine; Mutation; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oligopeptides; Pain Measurement; Patch-Clamp Techniques; Pertussis Toxin; Protein Binding; Reaction Time; RGS Proteins; Signal Transduction; Spinal Cord | 2013 |
'Miracle cure' or 'liquid handcuffs': reporting on naltrexone and methadone in the Australian print media.
Topics: Australia; Heroin Dependence; Humans; Mass Media; Methadone; Naltrexone; Newspapers as Topic; Opiate Substitution Treatment; Public Opinion; Treatment Outcome | 2014 |
Comment on "Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naive methadone-intoxicated patients".
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Naltrexone; Respiration Disorders | 2014 |
Informed consent abandoned--patient given contraindicated drug.
Topics: Alcoholism; Contraindications; Depressive Disorder; Humans; Informed Consent; Male; Medication Reconciliation; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Pain; Risk Management; Treatment Outcome | 2014 |
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Heroin; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Research Design; Systematic Reviews as Topic | 2014 |
Excess mortality among opioid-using patients treated with oral naltrexone in Australia.
Topics: Administration, Oral; Australia; Cohort Studies; Humans; Methadone; Naltrexone; Narcotic Antagonists; New South Wales; Opiate Substitution Treatment; Opioid-Related Disorders; Washington | 2015 |
Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Topics: Adolescent; Adult; Aged; Buprenorphine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Humans; Injections; Male; Markov Chains; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2015 |
Comment on "Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naive methadone-intoxicated patients".
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Naltrexone; Respiration Disorders | 2015 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
Mediation of opioid analgesia by a truncated 6-transmembrane GPCR.
Topics: Alternative Splicing; Analgesics, Opioid; Animals; Exons; Gene Targeting; Methadone; Mice; Mice, Knockout; Morphine; Naltrexone; Pain; Peptide Fragments; Protein Structure, Tertiary; Receptors, Opioid, mu; Recombinant Proteins | 2015 |
Severe opioid withdrawal syndrome after a single dose of nalmefene.
Topics: Adult; Alcoholism; Analgesics, Opioid; Codeine; Contraindications; Drug Interactions; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2015 |
Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
Topics: Behavior, Addictive; Buprenorphine; Global Health; Health Services Accessibility; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Misuse; United States | 2015 |
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pharmacovigilance; Substance Withdrawal Syndrome | 2015 |
Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Logistic Models; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Retrospective Studies; Social Justice; United States; United States Department of Veterans Affairs; Veterans | 2016 |
Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Interviews as Topic; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Preference; Substance Withdrawal Syndrome; Young Adult | 2016 |
A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Topics: Adult; Australia; Buprenorphine; Drug Administration Routes; Female; Humans; Incidence; Infant, Newborn; Male; Methadone; Naltrexone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Retrospective Studies | 2017 |
Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
Topics: Adult; Buprenorphine; Cohort Studies; Drug Implants; Drug Overdose; Female; Humans; Male; Methadone; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Risk Factors; Western Australia; Young Adult | 2017 |
A retrospective cohort study of the health of children prenatally exposed to methadone, buprenorphine or naltrexone compared with non-exposed control children.
Topics: Adult; Buprenorphine; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Longitudinal Studies; Male; Methadone; Naltrexone; Pregnancy; Prenatal Exposure Delayed Effects; Retrospective Studies; Western Australia | 2017 |
Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2018 |
Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Cross-Sectional Studies; Female; Humans; Injections, Intramuscular; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans; Veterans Health | 2018 |
Healthcare utilization and costs associated with treatment for opioid dependence.
Topics: Adult; Age Factors; Buprenorphine; Comorbidity; Counseling; Delayed-Action Preparations; Health Expenditures; Health Resources; Humans; Male; Methadone; Middle Aged; Models, Econometric; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2018 |
Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction.
Topics: Animals; Brain; Caudate Nucleus; Cerebral Cortex; Hippocampus; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Putamen; Rats, Sprague-Dawley | 2019 |
Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.
Topics: Adolescent; Adult; Buprenorphine; Cause of Death; Drug Overdose; Female; Fentanyl; Health Plan Implementation; Humans; Male; Methadone; Middle Aged; Naltrexone; Odds Ratio; Opioid-Related Disorders; Patient Discharge; Prisoners; Prisons; Retrospective Studies; Rhode Island; Transitional Care; Young Adult | 2018 |
Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury.
Topics: Analgesics, Opioid; Brain Injuries, Traumatic; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain; Receptors, Opioid, mu | 2018 |
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Middle Aged; Mortality; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Young Adult | 2018 |
Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.
Topics: Buprenorphine; Drug Approval; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Primary Health Care; United States; United States Food and Drug Administration | 2018 |
Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report.
Topics: Analgesics, Opioid; Colonic Pseudo-Obstruction; Constipation; Decompression, Surgical; Humans; Hydromorphone; Intestinal Perforation; Low Back Pain; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Postoperative Complications; Quaternary Ammonium Compounds; Spinal Stenosis | 2019 |
High drug related mortality rates following prison release: Assessing the acceptance likelihood of a naltrexone injection and related concerns.
Topics: Adult; Dose-Response Relationship, Drug; England; Heroin Dependence; Humans; Injections; Likelihood Functions; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Acceptance of Health Care; Prisoners; Young Adult | 2018 |
Overview of Drugs Used to Treat Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Nurse's Role; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic | 2018 |
Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Cohort Studies; Crime; Drug Overdose; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Factors; Suicidal Ideation; Young Adult | 2018 |
Telemedicine's Role in Addressing the Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Epidemics; Health Policy; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Telemedicine; United States | 2018 |
[Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database].
Topics: Analgesics, Opioid; Databases, Factual; Drug Labeling; France; Humans; Methadone; Naltrexone; Narcotic Antagonists; Pharmacovigilance | 2019 |
The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System.
Topics: Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Rhode Island; United States | 2018 |
Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Topics: Adolescent; Behavior Therapy; Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Retention in Care; Retrospective Studies; Time Factors; United States; Young Adult | 2018 |
Involvement of central opioid receptors in protective effects of methadone on experimental colitis in rats.
Topics: Acetic Acid; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Injections, Intraventricular; Injections, Subcutaneous; Interleukin-1beta; Intestinal Mucosa; Male; Methadone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid; Tumor Necrosis Factor-alpha | 2018 |
Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.
Topics: Buprenorphine; Hospitals, Veterans; Humans; Implementation Science; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality Improvement; Quality Indicators, Health Care; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Hospitals, Veterans; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Residential Treatment; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Nurse Practitioners; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Nurses'; United States | 2019 |
Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
Topics: Analgesics, Opioid; Buprenorphine; Diagnostic and Statistical Manual of Mental Disorders; Evidence-Based Medicine; Humans; International Classification of Diseases; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Reported Outcome Measures; Remission Induction | 2019 |
Suppression of Human Natural Killer Cells by Different Classes of Opioids.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Anesthesia; Buprenorphine; Enkephalin, D-Penicillamine (2,5)-; Fentanyl; Fluoresceins; Humans; Immunosuppression Therapy; K562 Cells; Killer Cells, Natural; Loperamide; Methadone; Morphinans; Morphine; Naloxone; Naltrexone; Succinimides; Toll-Like Receptor 4; Tramadol | 2019 |
Prescription Drug and Alcohol Use Disorders: Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2019 |
A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2019 |
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug Substitution; Female; Humans; Loperamide; Methadone; Methocarbamol; Muscle Relaxants, Central; Naltrexone; Narcotic Antagonists; Ondansetron; Opiate Substitution Treatment; Opioid-Related Disorders; Promethazine; Substance Withdrawal Syndrome; Sympatholytics | 2019 |
Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity.
Topics: Adult; Aged; Analgesics, Opioid; Antidepressive Agents; Buprenorphine; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Methadone; Middle Aged; Naltrexone; Treatment Outcome | 2019 |
News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Female; Health Education; Health Information Management; Humans; Information Dissemination; Male; Mass Media; Medical Informatics; Methadone; Naltrexone; Needs Assessment; Opiate Substitution Treatment; Opioid Epidemic; Opioid-Related Disorders; Public Health; Retrospective Studies; Risk Assessment; United States | 2019 |
Methadone's effects on pentylenetetrazole-induced seizure threshold in mice: NMDA/opioid receptors and nitric oxide signaling.
Topics: Animals; Anticonvulsants; Dizocilpine Maleate; Guanidines; Indazoles; Ketamine; Male; Methadone; Mice; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pentylenetetrazole; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Seizures | 2019 |
Medication-Based Treatment to Address Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Stereotyping | 2019 |
The case for a medication first approach to the treatment of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Certification; Health Plan Implementation; Health Services Accessibility; Humans; Methadone; Missouri; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; State Government | 2019 |
Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Topics: Adolescent; Adult; Age Factors; Buprenorphine; Drug Utilization; Female; Humans; Male; Medicaid; Methadone; Middle Aged; Naltrexone; New York; Opiate Substitution Treatment; Opioid-Related Disorders; United States; Young Adult | 2019 |
Use of naltrexone in treating opioid use disorder in pregnancy.
Topics: Abortion, Spontaneous; Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Prospective Studies; Stillbirth; Young Adult | 2020 |
US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.
Topics: Buprenorphine; Drug Overdose; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Retrospective Studies; United States | 2020 |
Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Health Services Accessibility; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Young Adult | 2019 |
Optimising opioid substitution therapy in the prison environment.
Topics: Age Factors; Buprenorphine; Comorbidity; Continuity of Patient Care; Delayed-Action Preparations; Drug Administration Schedule; England; Hepatitis C; HIV Infections; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Needle Sharing; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Quality Improvement; Social Work; Wales | 2019 |
Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.
Topics: Adolescent; Adult; Attitude; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; United States; Young Adult | 2020 |
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Continuity of Patient Care; Delayed-Action Preparations; Female; Health Services Accessibility; Humans; Interviews as Topic; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Satisfaction; Prisoners; Qualitative Research; Socioeconomic Factors | 2019 |
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Topics: Adolescent; Adult; Age Distribution; Analgesics, Opioid; Buprenorphine; Databases, Factual; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Time-to-Treatment; Young Adult | 2020 |
Characteristics and current clinical practices of opioid treatment programs in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Abuse Treatment Centers; Surveys and Questionnaires; Telemedicine; United States | 2019 |
Medications for opioid use disorders: clinical and pharmacological considerations.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Topics: Analgesics, Opioid; Beneficence; Buprenorphine; Correctional Facilities; Evidence-Based Practice; Health Services Accessibility; Humans; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Personal Autonomy; Prisoners; Public Health; Social Justice | 2020 |
Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Humans; Medicare; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2020 |
Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Endocarditis; Female; Humans; Injections; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Compliance; Patient Discharge; Retrospective Studies; Treatment Refusal | 2020 |
Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Health Services Accessibility; Humans; Medicaid; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Residential Treatment; Substance Abuse Treatment Centers; United States | 2020 |
Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cause of Death; Cohort Studies; Drug Overdose; Female; Humans; Male; Maryland; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Time Factors; United States; Young Adult | 2020 |
Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Residential Treatment; Retrospective Studies; Substance Withdrawal Syndrome; Young Adult | 2020 |
Diagnosis and Treatment of Opioid Use Disorder in 2020.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Drug and Narcotic Control; Harm Reduction; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Psychotherapy; Sensitivity and Specificity | 2020 |
Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Criminals; Cross-Sectional Studies; Drug Industry; Florida; Humans; Judicial Role; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Problem Solving | 2020 |
Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Topics: Ambulatory Care Facilities; Analgesics, Opioid; Buprenorphine; Delivery of Health Care; Health Services Accessibility; Hospitals, Veterans; Humans; Implementation Science; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Clinics; Primary Health Care; Teacher Training; United States; United States Department of Veterans Affairs; Veterans Health Services | 2020 |
Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Physicians, Primary Care; Primary Health Care; Surveys and Questionnaires; United States | 2020 |
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Behavior Therapy; Buprenorphine; Cohort Studies; Female; Health Care Costs; Hospitalization; Humans; Male; Medicare; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2020 |
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Buprenorphine; Delayed-Action Preparations; Drug and Narcotic Control; Female; Humans; Insurance Coverage; Insurance, Health; Male; Mental Disorders; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Specialization; United States | 2020 |
Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Case Managers; Counselors; Criminal Law; Criminals; Cross-Sectional Studies; Female; Florida; Health Knowledge, Attitudes, Practice; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Perioperative analgesia associated with oral administration of a novel methadone-fluconazole-naltrexone formulation in dogs undergoing routine ovariohysterectomy.
Topics: Administration, Oral; Analgesia; Analgesics, Opioid; Animals; Dog Diseases; Dogs; Female; Fluconazole; Humans; Hysterectomy; Methadone; Naltrexone; Ovariectomy; Pain, Postoperative | 2020 |
Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.
Topics: Adult; Buprenorphine; Female; Humans; Interprofessional Relations; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Care Team; United States | 2021 |
Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
Topics: Buprenorphine; Electrocardiography; Ether-A-Go-Go Potassium Channels; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Ion Channel Gating; Methadone; Myocytes, Cardiac; Naloxone; Naltrexone; Potassium Channel Blockers; Receptors, Opioid; Time Factors | 2020 |
COVID-19 and treating incarcerated populations for opioid use disorder.
Topics: Buprenorphine; COVID-19; Humans; Massachusetts; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners; Prisons; Public Health; Telemedicine | 2021 |
A study of the effectiveness of naltrexone in preventing recurrence of methadone poisoning in opioid-naive children.
Topics: Adolescent; Aftercare; Analgesics, Opioid; Child; Child, Preschool; Female; Hospitalization; Humans; Infant; Intensive Care Units; Iran; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Neoplasms; Patient Discharge; Poisoning; Recurrence; Retrospective Studies | 2021 |
The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Health Questionnaire | 2021 |
An anesthesiologist-led inpatient buprenorphine initiative.
Topics: Analgesics, Opioid; Anesthesiologists; Buprenorphine; Humans; Inpatients; Methadone; Naltrexone; Opioid-Related Disorders | 2021 |
Medication for Adolescents and Young Adults With Opioid Use Disorder.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Young Adult | 2021 |
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Topics: Accidental Falls; Adult; Alcohol-Related Disorders; Alcoholism; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; Drug Overdose; Ethanol; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Protective Factors; Wounds and Injuries; Young Adult | 2021 |
Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Animals; Dog Diseases; Dogs; Fluconazole; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2021 |
Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Family; Female; Goals; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Perception; Professional-Family Relations; Treatment Outcome | 2021 |
Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
Topics: Ambulatory Care; Buprenorphine; COVID-19; Health Services Accessibility; Humans; Insurance, Health, Reimbursement; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Telemedicine; United States | 2021 |
Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Cross-Sectional Studies; Drug Monitoring; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; United States; Young Adult | 2021 |
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
Topics: Alcoholism; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities.
Topics: Alcoholism; Anorexia Nervosa; Attention Deficit Disorder with Hyperactivity; Comorbidity; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Patient Outcome Assessment; Schizophrenia; Smoking; Varenicline | 2021 |
A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain | 2021 |
Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Hospital Mortality; Humans; Length of Stay; Logistic Models; Male; Methadone; Middle Aged; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; Prospective Studies | 2022 |
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Female; Humans; Medicaid; Methadone; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Quality of Life; United States; Young Adult | 2022 |
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cost Sharing; Female; Health Expenditures; Humans; Insurance, Health; Male; Medication Adherence; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States; Young Adult | 2022 |
Perioperative Management of Patients on Maintenance Medication for Addiction Treatment: The Development of an Institutional Guideline.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Understanding and co-managing medication treatment options for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2022 |
Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.
Topics: Analgesics, Opioid; Buprenorphine; Housing; Humans; Methadone; Missouri; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain; Prospective Studies | 2022 |
Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19 Drug Treatment; Cross-Sectional Studies; Health Services Accessibility; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Surveys and Questionnaires | 2022 |
Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis.
Topics: Analgesics, Opioid; Buprenorphine; Bupropion; Central Nervous System Stimulants; Cross-Over Studies; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Infant, Newborn; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners; Retrospective Studies | 2022 |
Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
Topics: Actigraphy; Analgesics, Opioid; Animals; Buprenorphine; Humans; Macaca mulatta; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Sleep | 2022 |
Methadone use is associated with increased levels of sCD14, immune activation, and inflammation during suppressed HIV infection.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Cytokines; HIV Infections; Humans; Immunoglobulin G; Inflammation; Lipopolysaccharide Receptors; Methadone; Naltrexone; Pilot Projects; Receptors, Opioid, mu | 2022 |
Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Nurse Practitioners; Opiate Substitution Treatment; Opioid-Related Disorders; Physician Assistants | 2022 |
Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Topics: Analgesics, Opioid; Buprenorphine; Child; Female; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Treatment Outcome | 2022 |
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Topics: Aged; Analgesics, Opioid; Buprenorphine; COVID-19; Drug Overdose; Female; Humans; Longitudinal Studies; Male; Medicare; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemics; Telemedicine; United States | 2022 |
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Delivery of Health Care; Humans; Medicaid; Methadone; Naltrexone; Opioid-Related Disorders; Primary Health Care; United States | 2022 |
Optimally Choosing Medication Type for Patients With Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder.
Topics: Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Augmenting project ECHO for opioid use disorder with data-informed quality improvement.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Quality Improvement; Surveys and Questionnaires | 2023 |
Ventricular Arrhythmias Associated With Over-the-Counter and Recreational Opioids.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Diphenoxylate; Humans; Loperamide; Methadone; Naltrexone; Nonprescription Drugs | 2023 |
Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Topics: Buprenorphine; Humans; Long QT Syndrome; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions; Retrospective Studies; United States | 2023 |
Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances.
Topics: Analgesics, Opioid; Buprenorphine; Cocaine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |